menu
    • menu
    [{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Micafungin","moa":"1,3-beta-glucan synthase","graph1":"Immunology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Antibiotic","year":"2013","type":"Inapplicable","leadProduct":"RHB-104","moa":"50S ribosomal subunit","graph1":"Immunology","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Leiden University Medical Center","sponsor":"NMD PHARMA","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Pyridostigmine","moa":"Acetylcholinesterase","graph1":"Immunology","graph2":"Phase III","graph3":"Leiden University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Leiden University Medical Center \/ NMD PHARMA","highestDevelopmentStatusID":"10","companyTruncated":"Leiden University Medical Center \/ NMD PHARMA"},{"orgOrder":0,"company":"Johns Hopkins University","sponsor":"Allergan","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Onabotulinumtoxin A","moa":"ACh release","graph1":"Immunology","graph2":"Phase III","graph3":"Johns Hopkins University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johns Hopkins University \/ Allergan","highestDevelopmentStatusID":"10","companyTruncated":"Johns Hopkins University \/ Allergan"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Bimagrumab","moa":"Activin receptor type-2B","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Bimagrumab","moa":"Activin receptor type-2B","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Bimagrumab","moa":"Activin receptor type-2B","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Genor Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"GB242","moa":"Adalimumab target","graph1":"Immunology","graph2":"Phase III","graph3":"Genor Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genor Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Genor Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Belhaven Biopharma","sponsor":"Lovelace Biomedical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Belhaven Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Belhaven Biopharma \/ Lovelace Biomedical","highestDevelopmentStatusID":"10","companyTruncated":"Belhaven Biopharma \/ Lovelace Biomedical"},{"orgOrder":0,"company":"Belhaven Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Belhaven Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Belhaven Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Belhaven Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Belhaven Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Financing","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Belhaven Biopharma","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Powder","sponsorNew":"Belhaven Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Belhaven Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Bryn Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Bryn Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Bryn Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bryn Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Bryn Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Financing","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Bryn Pharma","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.029999999999999999,"dosageForm":"Spray","sponsorNew":"Bryn Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bryn Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Bryn Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Bryn Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Bryn Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bryn Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Bryn Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Bryn Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Bryn Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bryn Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Bryn Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Bryn Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Bryn Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bryn Pharma \/ Undisclosed"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Seqirus","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Licensing Agreement","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase III","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ Seqirus","highestDevelopmentStatusID":"10","companyTruncated":"ARS Pharmaceuticals \/ Seqirus"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aquestive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aquestive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Belhaven Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Series A Financing","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Belhaven Biopharma","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Powder","sponsorNew":"Belhaven Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Belhaven Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Phenylephrine Hydrochloride","moa":"Adrenergic receptor alpha-1","graph1":"Immunology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Phenylephrine Hydrochloride","moa":"Adrenergic receptor alpha-1","graph1":"Immunology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Ocugen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","graph1":"Immunology","graph2":"Phase III","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ocugen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ocugen \/ Undisclosed"},{"orgOrder":0,"company":"Ocugen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","graph1":"Immunology","graph2":"Phase III","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ocugen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ocugen \/ Undisclosed"},{"orgOrder":0,"company":"Khon Kaen University","sponsor":"Farmaline","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"THAILAND","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2016","type":"Inapplicable","leadProduct":"Sodium Chloride","moa":"Adrenergic receptor Alpha-2 (ADRA2)","graph1":"Immunology","graph2":"Phase III","graph3":"Khon Kaen University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Khon Kaen University \/ Farmaline","highestDevelopmentStatusID":"10","companyTruncated":"Khon Kaen University \/ Farmaline"},{"orgOrder":0,"company":"University Hospital, Clermont-Ferrand","sponsor":"3i Nature | Naturop\u00f4le Nutrition sant\u00e9","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2014","type":"Inapplicable","leadProduct":"Curcumin","moa":"Albendazole monooxygenase (CYP3A4)","graph1":"Immunology","graph2":"Phase III","graph3":"University Hospital, Clermont-Ferrand","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital, Clermont-Ferrand \/ 3i Nature | Naturop\u00f4le Nutrition sant\u00e9","highestDevelopmentStatusID":"10","companyTruncated":"University Hospital, Clermont-Ferrand \/ 3i Nature | Naturop\u00f4le Nutrition sant\u00e9"},{"orgOrder":0,"company":"ALK","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"5-grass Mix Allergen Extract","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase III","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"ALK \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"ALK \/ Syneos Health"},{"orgOrder":0,"company":"Beijing Tongren Hospital","sponsor":"Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2019","type":"Inapplicable","leadProduct":"Artemisia Annua Allergen Extract","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase III","graph3":"Beijing Tongren Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Beijing Tongren Hospital \/ Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.","highestDevelopmentStatusID":"10","companyTruncated":"Beijing Tongren Hospital \/ Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd."},{"orgOrder":0,"company":"Stallergenes Greer","sponsor":"Quintiles Inc | Evotec | Cenduit | PHT Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Plant Extract\/Herbal","year":"2012","type":"Inapplicable","leadProduct":"Birch Pollen Allergen Extract","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase III","graph3":"Stallergenes Greer","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Stallergenes Greer \/ Quintiles Inc | Evotec | Cenduit | PHT Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Stallergenes Greer \/ Quintiles Inc | Evotec | Cenduit | PHT Corporation"},{"orgOrder":0,"company":"LETI Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Plant Extract\/Herbal","year":"2012","type":"Inapplicable","leadProduct":"Depigoid Birch","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase III","graph3":"LETI Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LETI Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"LETI Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Inmunotek","sponsor":"BioClever 2005 | NTS Hub S.L.","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Dermatophagoides Pteronyssinus","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase III","graph3":"Inmunotek","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inmunotek \/ BioClever 2005 | NTS Hub S.L.","highestDevelopmentStatusID":"10","companyTruncated":"Inmunotek \/ BioClever 2005 | NTS Hub S.L."},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2014","type":"Inapplicable","leadProduct":"Phleum Pratense Allergen Extract","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase III","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Abbott Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abbott Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"HAL Allergy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Purethal Birch","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase III","graph3":"HAL Allergy","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HAL Allergy \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"HAL Allergy \/ Undisclosed"},{"orgOrder":0,"company":"HAL Allergy","sponsor":"Ergomed | ClinCompetence Cologne GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Purethal Mites","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase III","graph3":"HAL Allergy","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"HAL Allergy \/ Ergomed | ClinCompetence Cologne GmbH","highestDevelopmentStatusID":"10","companyTruncated":"HAL Allergy \/ Ergomed | ClinCompetence Cologne GmbH"},{"orgOrder":0,"company":"ALK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Plant Extract\/Herbal","year":"2010","type":"Inapplicable","leadProduct":"Timothy Grass Pollen Allergen Extract","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase III","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ALK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ALK \/ Undisclosed"},{"orgOrder":0,"company":"ALK","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Tree Slit","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase III","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ALK \/ Parexel","highestDevelopmentStatusID":"10","companyTruncated":"ALK \/ Parexel"},{"orgOrder":0,"company":"Academisch Medisch Centrum - Universiteit van Amsterdam","sponsor":"ZonMw","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Mercaptopurine","moa":"Amidophosphoribosyltransferase | DNA","graph1":"Immunology","graph2":"Phase III","graph3":"Academisch Medisch Centrum - Universiteit van Amsterdam","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Academisch Medisch Centrum - Universiteit van Amsterdam \/ ZonMw","highestDevelopmentStatusID":"10","companyTruncated":"Academisch Medisch Centrum - Universiteit van Amsterdam \/ ZonMw"},{"orgOrder":0,"company":"Leadiant Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Amino Acid","year":"2012","type":"Inapplicable","leadProduct":"Propionylcarnitine","moa":"Amino acid metabolism","graph1":"Immunology","graph2":"Phase III","graph3":"Leadiant Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Leadiant Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Leadiant Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Leadiant Biosciences","sponsor":"PRA Health Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Amino Acid","year":"2012","type":"Inapplicable","leadProduct":"Propionylcarnitine","moa":"Amino acid metabolism","graph1":"Immunology","graph2":"Phase III","graph3":"Leadiant Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Leadiant Biosciences \/ PRA Health Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Leadiant Biosciences \/ PRA Health Sciences"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Imlifidase","moa":"Antibodies","graph1":"Immunology","graph2":"Phase III","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hansa Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2019","type":"Inapplicable","leadProduct":"Imlifidase","moa":"Antibodies","graph1":"Immunology","graph2":"Phase III","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hansa Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Imlifidase","moa":"||Antibodies","graph1":"Immunology","graph2":"Phase III","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hansa Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Antibodies","graph1":"Immunology","graph2":"Phase III","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hansa Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Antibodies","graph1":"Immunology","graph2":"Phase III","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hansa Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Imlifidase","moa":"Antibodies","graph1":"Immunology","graph2":"Phase III","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hansa Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2025","type":"Inapplicable","leadProduct":"Imlifidase","moa":"Antibodies","graph1":"Immunology","graph2":"Phase III","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hansa Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Imlifidase","moa":"Antibodies","graph1":"Immunology","graph2":"Phase III","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hansa Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Imlifidase","moa":"Antibodies","graph1":"Immunology","graph2":"Phase III","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hansa Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Imlifidase","moa":"Antibodies","graph1":"Immunology","graph2":"Phase III","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hansa Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Imlifidase","moa":"Antibodies","graph1":"Immunology","graph2":"Phase III","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hansa Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2019","type":"Inapplicable","leadProduct":"Imlifidase","moa":"Antibodies","graph1":"Immunology","graph2":"Phase III","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hansa Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hansa Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Antibiotic","year":"2017","type":"Inapplicable","leadProduct":"Clarithromycin","moa":"Bacterial 70S ribosome","graph1":"Immunology","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Antibiotic","year":"2021","type":"Public Offering","leadProduct":"Clarithromycin","moa":"||Bacterial 70S ribosome","graph1":"Immunology","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Antibiotic","year":"2021","type":"Public Offering","leadProduct":"Clarithromycin","moa":"||Bacterial 70S ribosome","graph1":"Immunology","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Clarithromycin","moa":"||Bacterial 70S ribosome","graph1":"Immunology","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Clarithromycin","moa":"||Bacterial 70S ribosome","graph1":"Immunology","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Public Offering","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Immunology","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.080000000000000002,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Immunology","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Immunology","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Immunology","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Immunology","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Salix Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Antibiotic","year":"2014","type":"Inapplicable","leadProduct":"Rifaximin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Immunology","graph2":"Phase III","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bausch Health \/ Salix Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Bausch Health \/ Salix Pharmaceuticals"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Salix Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Antibiotic","year":"2014","type":"Inapplicable","leadProduct":"Rifaximin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Immunology","graph2":"Phase III","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bausch Health \/ Salix Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Bausch Health \/ Salix Pharmaceuticals"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2020","type":"Inapplicable","leadProduct":"131-I Apamistamab","moa":"BC8","graph1":"Immunology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actinium pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Actinium pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2021","type":"Inapplicable","leadProduct":"131-I Apamistamab","moa":"BC8","graph1":"Immunology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actinium pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Actinium pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2020","type":"Inapplicable","leadProduct":"131-I Apamistamab","moa":"BC8","graph1":"Immunology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actinium pharmaceuticals \/ Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"10","companyTruncated":"Actinium pharmaceuticals \/ Memorial Sloan Kettering Cancer Center"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Descartes-08","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Immunology","graph2":"Phase III","graph3":"Cartesian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cartesian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cartesian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"Descartes-08","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Immunology","graph2":"Phase III","graph3":"Cartesian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cartesian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cartesian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Descartes-08","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Immunology","graph2":"Phase III","graph3":"Cartesian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cartesian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cartesian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Descartes-08","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Immunology","graph2":"Phase III","graph3":"Cartesian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cartesian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cartesian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Descartes-08","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Immunology","graph2":"Phase III","graph3":"Cartesian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cartesian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cartesian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Private Placement","leadProduct":"Descartes-08","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Immunology","graph2":"Phase III","graph3":"Cartesian Therapeutics","amount2":0.13,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.13,"dosageForm":"Infusion","sponsorNew":"Cartesian Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"10","companyTruncated":"Cartesian Therapeutics \/ Leerink Partners"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Descartes-08","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Immunology","graph2":"Phase III","graph3":"Cartesian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cartesian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cartesian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Descartes-08","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Immunology","graph2":"Phase III","graph3":"Cartesian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cartesian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cartesian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Descartes-08","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Immunology","graph2":"Phase III","graph3":"Cartesian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cartesian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cartesian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Inebilizumab","moa":"B-lymphocyte antigen CD19","graph1":"Immunology","graph2":"Phase III","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mitsubishi Tanabe Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mitsubishi Tanabe Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Inebilizumab","moa":"B-lymphocyte antigen CD19","graph1":"Immunology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Inebilizumab","moa":"B-lymphocyte antigen CD19","graph1":"Immunology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"BI695500","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"BI695500","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"CT-P10","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase III","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Obinutuzumab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Ofatumumab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Ofatumumab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"University Hospital, Tours","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase III","graph3":"University Hospital, Tours","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University Hospital, Tours \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"University Hospital, Tours \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"University Hospital, Tours","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase III","graph3":"University Hospital, Tours","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University Hospital, Tours \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"University Hospital, Tours \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"PPD","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase III","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dr. Reddy\\'s Laboratories \/ PPD","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Reddy\\'s Laboratories \/ PPD"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase III","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase III","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Henlius Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Henlius Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Assistance Publique \u2013 H\u00f4pitaux de Paris","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase III","graph3":"Assistance Publique \u2013 H\u00f4pitaux de Paris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Assistance Publique \u2013 H\u00f4pitaux de Paris","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase III","graph3":"Assistance Publique \u2013 H\u00f4pitaux de Paris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ GSK"},{"orgOrder":0,"company":"Cambridge University Hospitals NHS Foundation Trust","sponsor":"Arthritis Research UK | F. Hoffmann-La Roche | Genentech | University of Pennsylvania","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase III","graph3":"Cambridge University Hospitals NHS Foundation Trust","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cambridge University Hospitals NHS Foundation Trust \/ Arthritis Research UK | F. Hoffmann-La Roche | Genentech | University of Pennsylvania","highestDevelopmentStatusID":"10","companyTruncated":"Cambridge University Hospitals NHS Foundation Trust \/ Arthritis Research UK | F. Hoffmann-La Roche | Genentech | University of Pennsylvania"},{"orgOrder":0,"company":"Mabion SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"POLAND","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase III","graph3":"Mabion SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mabion SA \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mabion SA \/ Undisclosed"},{"orgOrder":0,"company":"Mabion SA","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"POLAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase III","graph3":"Mabion SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mabion SA \/ Parexel","highestDevelopmentStatusID":"10","companyTruncated":"Mabion SA \/ Parexel"},{"orgOrder":0,"company":"Biocad","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"RUSSIA","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase III","graph3":"Biocad","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biocad \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biocad \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Genentech","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Genentech"},{"orgOrder":0,"company":"Imperial College London","sponsor":"Karolinska Institutet | Ohio State University | Dutch Working Party on Systemic Lupus Erythematosus | EULAR Lupus Nephritis Trial Network Study Group","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase III","graph3":"Imperial College London","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Imperial College London \/ Karolinska Institutet | Ohio State University | Dutch Working Party on Systemic Lupus Erythematosus | EULAR Lupus Nephritis Trial Network Study Group","highestDevelopmentStatusID":"10","companyTruncated":"Imperial College London \/ Karolinska Institutet | Ohio State University | Dutch Working Party on Systemic Lupus Erythematosus | EULAR Lupus Nephritis Trial Network Study Group"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Hexal AG","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase III","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sandoz B2B \/ Hexal AG","highestDevelopmentStatusID":"10","companyTruncated":"Sandoz B2B \/ Hexal AG"},{"orgOrder":0,"company":"RemeGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"RC18","moa":"BLyS\/APRIL","graph1":"Immunology","graph2":"Phase III","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RemeGen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RemeGen \/ Undisclosed"},{"orgOrder":0,"company":"RemeGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"RC18","moa":"BLyS\/APRIL","graph1":"Immunology","graph2":"Phase III","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RemeGen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RemeGen \/ Undisclosed"},{"orgOrder":0,"company":"RemeGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"RC18","moa":"BLyS\/APRIL","graph1":"Immunology","graph2":"Phase III","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RemeGen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RemeGen \/ Undisclosed"},{"orgOrder":0,"company":"RemeGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Telitacicept","moa":"BLyS\/APRIL","graph1":"Immunology","graph2":"Phase III","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"RemeGen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RemeGen \/ Undisclosed"},{"orgOrder":0,"company":"RemeGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Telitacicept","moa":"BLyS\/APRIL","graph1":"Immunology","graph2":"Phase III","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"RemeGen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RemeGen \/ Undisclosed"},{"orgOrder":0,"company":"RemeGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Telitacicept","moa":"BLyS\/APRIL","graph1":"Immunology","graph2":"Phase III","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"RemeGen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RemeGen \/ Undisclosed"},{"orgOrder":0,"company":"RemeGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Telitacicept","moa":"BLyS\/APRIL","graph1":"Immunology","graph2":"Phase III","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"RemeGen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RemeGen \/ Undisclosed"},{"orgOrder":0,"company":"RemeGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Telitacicept","moa":"||BLyS\/APRIL","graph1":"Immunology","graph2":"Phase III","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"RemeGen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RemeGen \/ Undisclosed"},{"orgOrder":0,"company":"RemeGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Telitacicept","moa":"BLyS\/APRIL","graph1":"Immunology","graph2":"Phase III","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"RemeGen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RemeGen \/ Undisclosed"},{"orgOrder":0,"company":"RemeGen","sponsor":"Vor Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2025","type":"Licensing Agreement","leadProduct":"Telitacicept","moa":"BLyS\/APRIL","graph1":"Immunology","graph2":"Phase III","graph3":"RemeGen","amount2":4.1299999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":4.1299999999999999,"dosageForm":"Injection","sponsorNew":"RemeGen \/ Vor Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"RemeGen \/ Vor Biopharma"},{"orgOrder":0,"company":"RemeGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Telitacicept","moa":"BLyS\/APRIL","graph1":"Immunology","graph2":"Phase III","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"RemeGen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RemeGen \/ Undisclosed"},{"orgOrder":0,"company":"RemeGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Telitacicept","moa":"BLyS\/APRIL","graph1":"Immunology","graph2":"Phase III","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RemeGen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RemeGen \/ Undisclosed"},{"orgOrder":0,"company":"RemeGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Telitacicept","moa":"BLyS\/APRIL","graph1":"Immunology","graph2":"Phase III","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RemeGen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RemeGen \/ Undisclosed"},{"orgOrder":0,"company":"RemeGen","sponsor":"Lilly Asia Ventures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2020","type":"Financing","leadProduct":"Telitacicept","moa":"BLyS\/APRIL","graph1":"Immunology","graph2":"Phase III","graph3":"RemeGen","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"RemeGen \/ Lilly Asia Ventures","highestDevelopmentStatusID":"10","companyTruncated":"RemeGen \/ Lilly Asia Ventures"},{"orgOrder":0,"company":"Vor Biopharma","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2025","type":"Private Placement","leadProduct":"Telitacicept","moa":"BLyS\/APRIL","graph1":"Immunology","graph2":"Phase III","graph3":"Vor Biopharma","amount2":0.17999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.17999999999999999,"dosageForm":"Injection","sponsorNew":"Vor Biopharma \/ RA Capital Management","highestDevelopmentStatusID":"10","companyTruncated":"Vor Biopharma \/ RA Capital Management"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"PPD","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Icatibant Acetate","moa":"Bradykinin B2 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SHIRE PLC \/ PPD","highestDevelopmentStatusID":"10","companyTruncated":"SHIRE PLC \/ PPD"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Remibrutinib","moa":"BTK||Tyrosine-protein kinase BTK (ATK)","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Remibrutinib","moa":"BTK||Tyrosine-protein kinase BTK (ATK)","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Remibrutinib","moa":"BTK||Tyrosine-protein kinase BTK (ATK)","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Remibrutinib","moa":"BTK||Tyrosine-protein kinase BTK (ATK)","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Remibrutinib","moa":"BTK||Tyrosine-protein kinase BTK (ATK)","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Remibrutinib","moa":"BTK||Tyrosine-protein kinase BTK (ATK)","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Remibrutinib","moa":"BTK||Tyrosine-protein kinase BTK (ATK)","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Remibrutinib","moa":"BTK||Tyrosine-protein kinase BTK (ATK)","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Remibrutinib","moa":"BTK","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Remibrutinib","moa":"BTK","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Remibrutinib","moa":"BTK","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Remibrutinib","moa":"BTK","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Remibrutinib","moa":"BTK","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Remibrutinib","moa":"BTK","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Remibrutinib","moa":"BTK","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Remibrutinib","moa":"BTK","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tolebrutininb","moa":"BTK","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Falk Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"LT-02","moa":"Butyrate-producing bacteria","graph1":"Immunology","graph2":"Phase III","graph3":"Dr. Falk Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dr. Falk Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Falk Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Falk Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"LT-02","moa":"Butyrate-producing bacteria","graph1":"Immunology","graph2":"Phase III","graph3":"Dr. Falk Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dr. Falk Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Falk Pharma \/ Undisclosed"},{"orgOrder":0,"company":"PROMETHEUS LABS","sponsor":"Nestle Health Sciences SA | Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"LT-02","moa":"Butyrate-producing bacteria","graph1":"Immunology","graph2":"Phase III","graph3":"PROMETHEUS LABS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PROMETHEUS LABS \/ Nestle Health Sciences SA | Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"PROMETHEUS LABS \/ Nestle Health Sciences SA | Syneos Health"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Tanruprubart","moa":"C1q","graph1":"Immunology","graph2":"Phase III","graph3":"Annexon Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Annexon Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Annexon Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Gefurulimab","moa":"C5","graph1":"Immunology","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alexion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"FK506E","moa":"Calcineurin","graph1":"Immunology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"National Institute of Arthritis and Musculoskeletal and Skin Diseases | University of Pennsylvania","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Lenabasum","moa":"cannabinol derivatives","graph1":"Immunology","graph2":"Phase III","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Corbus Pharmaceuticals \/ National Institute of Arthritis and Musculoskeletal and Skin Diseases | University of Pennsylvania","highestDevelopmentStatusID":"10","companyTruncated":"Corbus Pharmaceuticals \/ National Institute of Arthritis and Musculoskeletal and Skin Diseases | University of Pennsylvania"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Lenabasum","moa":"cannabinol derivatives","graph1":"Immunology","graph2":"Phase III","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Corbus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Corbus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lenabasum","moa":"cannabinol derivatives","graph1":"Immunology","graph2":"Phase III","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Corbus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Corbus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lenabasum","moa":"cannabinol derivatives","graph1":"Immunology","graph2":"Phase III","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Corbus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Corbus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Public Offering","leadProduct":"Lenabasum","moa":"cannabinol derivatives","graph1":"Immunology","graph2":"Phase III","graph3":"Corbus Pharmaceuticals","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.040000000000000001,"dosageForm":"Capsule","sponsorNew":"Corbus Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Corbus Pharmaceuticals \/ Jefferies"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lenabasum","moa":"cannabinol derivatives","graph1":"Immunology","graph2":"Phase III","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Corbus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Corbus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Lenabasum","moa":"cannabinol derivatives","graph1":"Immunology","graph2":"Phase III","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Corbus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Corbus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Lenabasum","moa":"cannabinol derivatives","graph1":"Immunology","graph2":"Phase III","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Corbus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Corbus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lenabasum","moa":"cannabinol derivatives","graph1":"Immunology","graph2":"Phase III","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Corbus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Corbus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Orion Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Orion Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Orion Corporation"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"TCGX","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Financing","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.050000000000000003,"dosageForm":"Capsule","sponsorNew":"Abivax \/ TCGX","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ TCGX"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Kreos Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Financing","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Kreos Capital","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Kreos Capital"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"TCGX","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Financing","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.050000000000000003,"dosageForm":"Capsule","sponsorNew":"Abivax \/ TCGX","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ TCGX"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Vercirnon","moa":"C-C chemokine receptor type 9||CCR9","graph1":"Immunology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Vercirnon","moa":"C-C chemokine receptor type 9||CCR9","graph1":"Immunology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Vercirnon","moa":"C-C chemokine receptor type 9||CCR9","graph1":"Immunology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Vercirnon","moa":"C-C chemokine receptor type 9||CCR9","graph1":"Immunology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Vercirnon","moa":"CCR9","graph1":"Immunology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Vercirnon","moa":"CCR9","graph1":"Immunology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Vercirnon","moa":"CCR9","graph1":"Immunology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Vercirnon","moa":"CCR9","graph1":"Immunology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"ABP 798","moa":"CD20","graph1":"Immunology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Biocad","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"RUSSIA","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Acellbia","moa":"CD20","graph1":"Immunology","graph2":"Phase III","graph3":"Biocad","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocad \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biocad \/ Undisclosed"},{"orgOrder":0,"company":"Biotest","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"BT595","moa":"CD20","graph1":"Immunology","graph2":"Phase III","graph3":"Biotest","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biotest \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Biotest \/ Syneos Health"},{"orgOrder":0,"company":"Biocad","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"RUSSIA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Divozilimab","moa":"CD20","graph1":"Immunology","graph2":"Phase III","graph3":"Biocad","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocad \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biocad \/ Undisclosed"},{"orgOrder":0,"company":"Genrix Biopharmaceutical Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"GR1501","moa":"CD20","graph1":"Immunology","graph2":"Phase III","graph3":"Genrix Biopharmaceutical Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genrix Biopharmaceutical Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Genrix Biopharmaceutical Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Genrix Biopharmaceutical Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"GR1501","moa":"CD20","graph1":"Immunology","graph2":"Phase III","graph3":"Genrix Biopharmaceutical Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genrix Biopharmaceutical Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Genrix Biopharmaceutical Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"HLX01","moa":"CD20","graph1":"Immunology","graph2":"Phase III","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Henlius Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Henlius Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"HLX01","moa":"CD20","graph1":"Immunology","graph2":"Phase III","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Henlius Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Henlius Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Navidea Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"99m-Tc Tilmanocept","moa":"CD206","graph1":"Immunology","graph2":"Phase III","graph3":"Navidea Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Navidea Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Navidea Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Navidea Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2019","type":"Inapplicable","leadProduct":"99m-Tc Tilmanocept","moa":"CD206","graph1":"Immunology","graph2":"Phase III","graph3":"Navidea Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Navidea Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Navidea Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Navidea Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2019","type":"Inapplicable","leadProduct":"99m-Tc Tilmanocept","moa":"CD206","graph1":"Immunology","graph2":"Phase III","graph3":"Navidea Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Navidea Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Navidea Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Navidea Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2021","type":"Inapplicable","leadProduct":"99m-Tc Tilmanocept","moa":"CD206","graph1":"Immunology","graph2":"Phase III","graph3":"Navidea Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Navidea Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Navidea Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Navidea Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2016","type":"Inapplicable","leadProduct":"99m-Tc Tilmanocept","moa":"CD206","graph1":"Immunology","graph2":"Phase III","graph3":"Navidea Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Navidea Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Navidea Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Epratuzumab","moa":"CD22","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Epratuzumab","moa":"CD22","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Epratuzumab","moa":"CD22","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Epratuzumab","moa":"CD22","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Epratuzumab","moa":"CD22","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Pharmaceutical Research Associates | Richmond Pharmacology | ACM Global Laboratories | Eurofins CDMO | The Doctors Laboratory Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Epratuzumab","moa":"CD22","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Pharmaceutical Research Associates | Richmond Pharmacology | ACM Global Laboratories | Eurofins CDMO | The Doctors Laboratory Ltd","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Pharmaceutical Research Associates | Richmond Pharmacology | ACM Global Laboratories | Eurofins CDMO | The Doctors Laboratory Ltd"},{"orgOrder":0,"company":"Xenikos B.V","sponsor":"National Heart, Lung, and Blood Institute | Blood and Marrow Transplant Clinical Trials Network | National Cancer Institute | National Marrow Donor Program","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"T-Guard","moa":"CD3\/7","graph1":"Immunology","graph2":"Phase III","graph3":"Xenikos B.V","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Xenikos B.V \/ National Heart, Lung, and Blood Institute | Blood and Marrow Transplant Clinical Trials Network | National Cancer Institute | National Marrow Donor Program","highestDevelopmentStatusID":"10","companyTruncated":"Xenikos B.V \/ National Heart, Lung, and Blood Institute | Blood and Marrow Transplant Clinical Trials Network | National Cancer Institute | National Marrow Donor Program"},{"orgOrder":0,"company":"Xenikos B.V","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"T-Guard","moa":"CD3\/7","graph1":"Immunology","graph2":"Phase III","graph3":"Xenikos B.V","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Xenikos B.V \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Xenikos B.V \/ Undisclosed"},{"orgOrder":0,"company":"Xenikos B.V","sponsor":"National Heart, Lung, and Blood Institute | Blood and Marrow Transplant Clinical Trials Network | National Cancer Institute | National Marrow Donor Program","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"T-Guard","moa":"CD3\/7","graph1":"Immunology","graph2":"Phase III","graph3":"Xenikos B.V","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xenikos B.V \/ National Heart, Lung, and Blood Institute | Blood and Marrow Transplant Clinical Trials Network | National Cancer Institute | National Marrow Donor Program","highestDevelopmentStatusID":"10","companyTruncated":"Xenikos B.V \/ National Heart, Lung, and Blood Institute | Blood and Marrow Transplant Clinical Trials Network | National Cancer Institute | National Marrow Donor Program"},{"orgOrder":0,"company":"Xenikos B.V","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Dafsolimab Setaritox","moa":"CD3\/7||CD3\/CD7","graph1":"Immunology","graph2":"Phase III","graph3":"Xenikos B.V","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xenikos B.V \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Xenikos B.V \/ Undisclosed"},{"orgOrder":0,"company":"Veloxis Pharmaceuticals","sponsor":"Xenikos B.V","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Dafsolimab Setaritox","moa":"CD3\/7||CD3\/CD7","graph1":"Immunology","graph2":"Phase III","graph3":"Veloxis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Veloxis Pharmaceuticals \/ Xenikos B.V","highestDevelopmentStatusID":"10","companyTruncated":"Veloxis Pharmaceuticals \/ Xenikos B.V"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Dapirolizumab Pegol","moa":"CD40 ligand","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Dapirolizumab Pegol","moa":"CD40 ligand","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Dapirolizumab Pegol","moa":"CD40 ligand","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Dapirolizumab Pegol","moa":"CD40 ligand","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Dapirolizumab Pegol","moa":"CD40 ligand","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UCB Pharma S.A \/ Biogen","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Biogen"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Dazodalibep","moa":"CD40 ligand","graph1":"Immunology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Dazodalibep","moa":"CD40 ligand","graph1":"Immunology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Dazodalibep","moa":"CD40 ligand","graph1":"Immunology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Xigen SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"XG-102","moa":"c-Jun N-terminal kinase 3","graph1":"Immunology","graph2":"Phase III","graph3":"Xigen SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Xigen SA \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Xigen SA \/ Undisclosed"},{"orgOrder":0,"company":"Xigen SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"XG-102","moa":"c-Jun N-terminal kinase 3","graph1":"Immunology","graph2":"Phase III","graph3":"Xigen SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xigen SA \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Xigen SA \/ Undisclosed"},{"orgOrder":0,"company":"Xigen SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"XG-102","moa":"c-Jun N-terminal kinase 3","graph1":"Immunology","graph2":"Phase III","graph3":"Xigen SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xigen SA \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Xigen SA \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"Coagulation factor X","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Bayer AG","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Bayer AG"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"ANX005","moa":"Complement C1s component (C1S)","graph1":"Immunology","graph2":"Phase III","graph3":"Annexon Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Annexon Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Annexon Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"ResearchPoint Global | International Centre for Diarrhoeal Disease Research, Bangladesh","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"ANX005","moa":"Complement C1s component (C1S)","graph1":"Immunology","graph2":"Phase III","graph3":"Annexon Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Annexon Biosciences \/ ResearchPoint Global | International Centre for Diarrhoeal Disease Research, Bangladesh","highestDevelopmentStatusID":"10","companyTruncated":"Annexon Biosciences \/ ResearchPoint Global | International Centre for Diarrhoeal Disease Research, Bangladesh"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"ANX005","moa":"Complement C1s component (C1S)","graph1":"Immunology","graph2":"Phase III","graph3":"Annexon Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Annexon Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Annexon Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Public Offering","leadProduct":"ANX005","moa":"Complement C1s component (C1S)","graph1":"Immunology","graph2":"Phase III","graph3":"Annexon Biosciences","amount2":0.13,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.13,"dosageForm":"Infusion","sponsorNew":"Annexon Biosciences \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Annexon Biosciences \/ J.P. Morgan"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Public Offering","leadProduct":"ANX005","moa":"Complement C1s component (C1S)","graph1":"Immunology","graph2":"Phase III","graph3":"Annexon Biosciences","amount2":0.13,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.13,"dosageForm":"Infusion","sponsorNew":"Annexon Biosciences \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Annexon Biosciences \/ J.P. Morgan"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"ANX005","moa":"Complement C1s component (C1S)","graph1":"Immunology","graph2":"Phase III","graph3":"Annexon Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Annexon Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Annexon Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Redmile Group","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Financing","leadProduct":"ANX005","moa":"Complement C1s component (C1S)","graph1":"Immunology","graph2":"Phase III","graph3":"Annexon Biosciences","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.10000000000000001,"dosageForm":"Infusion","sponsorNew":"Annexon Biosciences \/ Redmile Group","highestDevelopmentStatusID":"10","companyTruncated":"Annexon Biosciences \/ Redmile Group"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"ANX005","moa":"Complement C1s component (C1S)","graph1":"Immunology","graph2":"Phase III","graph3":"Annexon Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Annexon Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Annexon Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"ANX005","moa":"Complement C1s component (C1S)","graph1":"Immunology","graph2":"Phase III","graph3":"Annexon Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Annexon Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Annexon Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Crovalimab","moa":"Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Eculizumab","moa":"Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Samsung Bioepis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Samsung Bioepis \/ Undisclosed"},{"orgOrder":0,"company":"Cedars-Sinai","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Eculizumab","moa":"Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"Cedars-Sinai","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cedars-Sinai \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Cedars-Sinai \/ Alexion Pharmaceuticals"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Eculizumab","moa":"Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pozelimab","moa":"Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"Ra Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"Ra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ra Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ra Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ra Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"Ra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ra Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ra Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ra Pharmaceuticals","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Acquisition","leadProduct":"Zilucoplan Sodium","moa":"Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"Ra Pharmaceuticals","amount2":2.2999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":2.2999999999999998,"dosageForm":"Injection","sponsorNew":"Ra Pharmaceuticals \/ UCB Pharma S.A","highestDevelopmentStatusID":"10","companyTruncated":"Ra Pharmaceuticals \/ UCB Pharma S.A"},{"orgOrder":0,"company":"Ra Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"Ra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ra Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ra Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"ALXN1720","moa":"Complement C5 (CO5)","graph1":"Immunology","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alexion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Iptacopan Hydrochloride","moa":"Complement factor B","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Daewon Pharm. Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Pelubiprofen","moa":"anti-inflammatory\/analgesic agents (ibuprofen type)","graph1":"Immunology","graph2":"Phase III","graph3":"Daewon Pharm. Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daewon Pharm. Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Daewon Pharm. Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"INCA034176","moa":"CSF-1R","graph1":"Immunology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"INCA034176","moa":"CSF-1R","graph1":"Immunology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"INCA034176","moa":"CSF-1R","graph1":"Immunology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"INCA034176","moa":"CSF-1R","graph1":"Immunology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Litifilimab","moa":"C-type lectin domain family 4 member C","graph1":"Immunology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Litifilimab","moa":"C-type lectin domain family 4 member C","graph1":"Immunology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Litifilimab","moa":"C-type lectin domain family 4 member C","graph1":"Immunology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Litifilimab","moa":"C-type lectin domain family 4 member C","graph1":"Immunology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Litifilimab","moa":"C-type lectin domain family 4 member C","graph1":"Immunology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Litifilimab","moa":"C-type lectin domain family 4 member C","graph1":"Immunology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Litifilimab","moa":"C-type lectin domain family 4 member C","graph1":"Immunology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Litifilimab","moa":"C-type lectin domain family 4 member C","graph1":"Immunology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Litifilimab","moa":"C-type lectin domain family 4 member C","graph1":"Immunology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Litifilimab","moa":"C-type lectin domain family 4 member C","graph1":"Immunology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Litifilimab","moa":"C-type lectin domain family 4 member C","graph1":"Immunology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Feinstein Institutes","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Litifilimab","moa":"C-type lectin domain family 4 member C","graph1":"Immunology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biogen \/ Feinstein Institutes","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Feinstein Institutes"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Litifilimab","moa":"C-type lectin domain family 4 member C","graph1":"Immunology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Collaboration","leadProduct":"Litifilimab","moa":"C-type lectin domain family 4 member C","graph1":"Immunology","graph2":"Phase III","graph3":"Biogen","amount2":0.25,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.25,"dosageForm":"Injection","sponsorNew":"Biogen \/ Royalty Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Royalty Pharma"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Litifilimab","moa":"C-type lectin domain family 4 member C","graph1":"Immunology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"Cyclooxygenase","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Mesalazine","moa":"Cyclooxygenase | Peroxisome proliferator-activated receptor gamma | Arachidonate 5-lipoxygenase","graph1":"Immunology","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"Ferring Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Tillotts Pharma AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Mesalazine","moa":"Cyclooxygenase | Peroxisome proliferator-activated receptor gamma | Arachidonate 5-lipoxygenase","graph1":"Immunology","graph2":"Phase III","graph3":"Tillotts Pharma AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tillotts Pharma AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tillotts Pharma AG \/ Undisclosed"},{"orgOrder":0,"company":"Tillotts Pharma AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Mesalazine","moa":"Cyclooxygenase | Peroxisome proliferator-activated receptor gamma | Arachidonate 5-lipoxygenase","graph1":"Immunology","graph2":"Phase III","graph3":"Tillotts Pharma AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tillotts Pharma AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tillotts Pharma AG \/ Undisclosed"},{"orgOrder":0,"company":"Tillotts Pharma AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Mesalazine","moa":"Cyclooxygenase | Peroxisome proliferator-activated receptor gamma | Arachidonate 5-lipoxygenase","graph1":"Immunology","graph2":"Phase III","graph3":"Tillotts Pharma AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tillotts Pharma AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tillotts Pharma AG \/ Undisclosed"},{"orgOrder":0,"company":"Tillotts Pharma AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Mesalazine","moa":"Cyclooxygenase | Peroxisome proliferator-activated receptor gamma | Arachidonate 5-lipoxygenase","graph1":"Immunology","graph2":"Phase III","graph3":"Tillotts Pharma AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tillotts Pharma AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tillotts Pharma AG \/ Undisclosed"},{"orgOrder":0,"company":"Faes Farma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Mesalazine","moa":"Cyclooxygenase | Peroxisome proliferator-activated receptor gamma | Arachidonate 5-lipoxygenase","graph1":"Immunology","graph2":"Phase III","graph3":"Faes Farma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Faes Farma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Faes Farma \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Falk Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Mesalazine","moa":"Cyclooxygenase | Peroxisome proliferator-activated receptor gamma | Arachidonate 5-lipoxygenase","graph1":"Immunology","graph2":"Phase III","graph3":"Dr. Falk Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dr. Falk Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Falk Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Organon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Etoricoxib","moa":"Cyclooxygenase-2","graph1":"Immunology","graph2":"Phase III","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Organon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Organon \/ Undisclosed"},{"orgOrder":0,"company":"Organon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Etoricoxib","moa":"Cyclooxygenase-2","graph1":"Immunology","graph2":"Phase III","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Organon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Organon \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Meloxicam","moa":"Cyclooxygenase-2","graph1":"Immunology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Cyclophilin A","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Organon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Montelukast Sodium","moa":"Cysteinyl leukotriene receptor 1","graph1":"Immunology","graph2":"Phase III","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Organon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Organon \/ Undisclosed"},{"orgOrder":0,"company":"Organon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Montelukast Sodium","moa":"Cysteinyl leukotriene receptor 1","graph1":"Immunology","graph2":"Phase III","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Chewable","sponsorNew":"Organon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Organon \/ Undisclosed"},{"orgOrder":0,"company":"Momenta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Dietary Supplement","year":"2016","type":"Inapplicable","leadProduct":"Spermidine","moa":"Cytoplasmic thioredoxin reductase (TXNRD1)||TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Momenta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Momenta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Momenta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"University of North Carolina","sponsor":"Patient-Centered Outcomes Research Institute | ImproveCareNow | Helmsley Charitable Trust | Children's Hospital Medical Center, Cincinnati | Grifols Diagnostics Solutions, Inc | National Institutes of Health | National Institute of Arthritis and Musculosk","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2016","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Immunology","graph2":"Phase III","graph3":"University of North Carolina","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of North Carolina \/ Patient-Centered Outcomes Research Institute | ImproveCareNow | Helmsley Charitable Trust | Children's Hospital Medical Center, Cincinnati | Grifols Diagnostics Solutions, Inc | National Institutes of Health | National Institute of Arthritis and Musculosk","highestDevelopmentStatusID":"10","companyTruncated":"University of North Carolina \/ Patient-Centered Outcomes Research Institute | ImproveCareNow | Helmsley Charitable Trust | Children's Hospital Medical Center, Cincinnati | Grifols Diagnostics Solutions, Inc | National Institutes of Health | National Institute of Arthritis and Musculosk"},{"orgOrder":0,"company":"Mycenax Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Immunology","graph2":"Phase III","graph3":"Mycenax Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mycenax Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mycenax Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2013","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Adienne","sponsor":"Adienne","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Begelomab","moa":"Dipeptidyl peptidase IV","graph1":"Immunology","graph2":"Phase III","graph3":"Adienne","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Adienne \/ Adienne","highestDevelopmentStatusID":"10","companyTruncated":"Adienne \/ Adienne"},{"orgOrder":0,"company":"Merck Group","sponsor":"EMD Serono","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Cladribine","moa":"DNA","graph1":"Immunology","graph2":"Phase III","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck Group \/ EMD Serono","highestDevelopmentStatusID":"10","companyTruncated":"Merck Group \/ EMD Serono"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Cladribine","moa":"DNA","graph1":"Immunology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"DKMS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"DNA","graph1":"Immunology","graph2":"Phase III","graph3":"DKMS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DKMS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"DKMS \/ Undisclosed"},{"orgOrder":0,"company":"CVC Capital Partners","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"LUXEMBOURG","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Methoxsalen","moa":"DNA","graph1":"Immunology","graph2":"Phase III","graph3":"CVC Capital Partners","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"CVC Capital Partners \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CVC Capital Partners \/ Undisclosed"},{"orgOrder":0,"company":"Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa","sponsor":"Effice Servicios Para la Investigacion","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Plant Extract\/Herbal","year":"2012","type":"Inapplicable","leadProduct":"Metronidazole","moa":"DNA","graph1":"Immunology","graph2":"Phase III","graph3":"Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa \/ Effice Servicios Para la Investigacion","highestDevelopmentStatusID":"10","companyTruncated":"Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa \/ Effice Servicios Para la Investigacion"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Azathioprine","moa":"DNA | Amidophosphoribosyltransferase","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Virginia Commonwealth University","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Letermovir","moa":"DNA terminase","graph1":"Immunology","graph2":"Phase III","graph3":"Virginia Commonwealth University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Virginia Commonwealth University \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Virginia Commonwealth University \/ Merck & Co"},{"orgOrder":0,"company":"Fujifilm Diosynth Biotechnologies","sponsor":"Atara Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2022","type":"Partnership","leadProduct":"Tabelecleucel","moa":"EBV","graph1":"Immunology","graph2":"Phase III","graph3":"Fujifilm Diosynth Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fujifilm Diosynth Biotechnologies \/ Atara Biotherapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Fujifilm Diosynth Biotechnologies \/ Atara Biotherapeutics"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"TD Cowen","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Public Offering","leadProduct":"Tabelecleucel","moa":"EBV","graph1":"Immunology","graph2":"Phase III","graph3":"Atara Biotherapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"Atara Biotherapeutics \/ TD Cowen","highestDevelopmentStatusID":"10","companyTruncated":"Atara Biotherapeutics \/ TD Cowen"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Macitentan","moa":"Endothelin receptor, ET-A\/ET-B","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"AllerQuest","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Amino Acid","year":"2013","type":"Inapplicable","leadProduct":"Benzylpenicilloyl G Polylysine","moa":"FCER1A","graph1":"Immunology","graph2":"Phase III","graph3":"AllerQuest","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AllerQuest \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AllerQuest \/ Undisclosed"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"||FcRn","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"FcRn","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Agreement","leadProduct":"Efgartigimod","moa":"FcRn","graph1":"Immunology","graph2":"Phase III","graph3":"Bluebird Bio","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.10000000000000001,"dosageForm":"Infusion","sponsorNew":"Bluebird Bio \/ Argenx","highestDevelopmentStatusID":"10","companyTruncated":"Bluebird Bio \/ Argenx"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Agreement","leadProduct":"Efgartigimod","moa":"FcRn","graph1":"Immunology","graph2":"Phase III","graph3":"Bluebird Bio","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.10000000000000001,"dosageForm":"Infusion","sponsorNew":"Bluebird Bio \/ Argenx","highestDevelopmentStatusID":"10","companyTruncated":"Bluebird Bio \/ Argenx"},{"orgOrder":0,"company":"Elektrofi","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Collaboration","leadProduct":"Efgartigimod","moa":"FcRn","graph1":"Immunology","graph2":"Phase III","graph3":"Elektrofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Elektrofi \/ Argenx","highestDevelopmentStatusID":"10","companyTruncated":"Elektrofi \/ Argenx"},{"orgOrder":0,"company":"Immunovant","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"IMVT-1402","moa":"FcRn","graph1":"Immunology","graph2":"Phase III","graph3":"Immunovant","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immunovant \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Immunovant \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"REGN5713","moa":"Fel d 1 (cat allergen)","graph1":"Immunology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"REGN5713","moa":"Fel d 1 (cat allergen)","graph1":"Immunology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Everolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Everolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Astellas Pharma \/ Astellas Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Astellas Pharma"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibiotic","year":"2012","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibiotic","year":"2014","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Medical College of Wisconsin","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2016","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase III","graph3":"Medical College of Wisconsin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Medical College of Wisconsin \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Medical College of Wisconsin \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Blood and Marrow Transplant Clinical Trials Network | National Institutes of Health | National Heart, Lung, and Blood Institute | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Blood and Marrow Transplant Clinical Trials Network | National Institutes of Health | National Heart, Lung, and Blood Institute | National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Blood and Marrow Transplant Clinical Trials Network | National Institutes of Health | National Heart, Lung, and Blood Institute | National Cancer Institute"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"ACT-129968","moa":"G protein-coupled receptor 44","graph1":"Immunology","graph2":"Phase III","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Idorsia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Idorsia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"ACT-129968","moa":"G protein-coupled receptor 44","graph1":"Immunology","graph2":"Phase III","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Idorsia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Idorsia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Marinomed Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRIA","productType":"Steroid","year":"2018","type":"Inapplicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Marinomed Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Marinomed Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Marinomed Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Marinomed Biotech","sponsor":"Luoxin Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"AUSTRIA","productType":"Steroid","year":"2021","type":"Licensing Agreement","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Marinomed Biotech","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.02,"dosageForm":"Spray","sponsorNew":"Marinomed Biotech \/ Luoxin Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Marinomed Biotech \/ Luoxin Pharmaceutical"},{"orgOrder":0,"company":"Azidus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BRAZIL","productType":"Steroid","year":"2010","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Azidus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Azidus \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Azidus \/ Undisclosed"},{"orgOrder":0,"company":"Azidus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BRAZIL","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Prednisolone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Azidus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Azidus \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Azidus \/ Undisclosed"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Beclomethasone Dipropionate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Teva Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Beclomethasone Dipropionate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Teva Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Beclomethasone Dipropionate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Teva Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Beclomethasone Dipropionate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Teva Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Padagis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Steroid","year":"2011","type":"Inapplicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Padagis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Padagis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Padagis \/ Undisclosed"},{"orgOrder":0,"company":"Padagis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Steroid","year":"2011","type":"Inapplicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Padagis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Padagis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Padagis \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Falk Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Steroid","year":"2010","type":"Inapplicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Dr. Falk Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dr. Falk Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Falk Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Steroid","year":"2018","type":"Inapplicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ferring Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Steroid","year":"2014","type":"Inapplicable","leadProduct":"Ciclesonide","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2011","type":"Inapplicable","leadProduct":"Ciclesonide","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Sumitomo Pharma America","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Sumitomo Pharma America \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Apotex Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Steroid","year":"2014","type":"Inapplicable","leadProduct":"Ciclesonide","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Apotex Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Apotex Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Apotex Inc \/ Undisclosed"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Formosa Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"JAPAN","productType":"Steroid","year":"2024","type":"Agreement","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sosei Group Corporation \/ Formosa Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Sosei Group Corporation \/ Formosa Laboratories"},{"orgOrder":0,"company":"Formosa Pharmaceuticals","sponsor":"Apotex Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Steroid","year":"2024","type":"Licensing Agreement","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Formosa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Formosa Pharmaceuticals \/ Apotex Inc","highestDevelopmentStatusID":"10","companyTruncated":"Formosa Pharmaceuticals \/ Apotex Inc"},{"orgOrder":0,"company":"Icon Bioscience Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2013","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Icon Bioscience Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Icon Bioscience Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Icon Bioscience Inc \/ Undisclosed"},{"orgOrder":0,"company":"Icon Bioscience Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2010","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Icon Bioscience Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Icon Bioscience Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Icon Bioscience Inc \/ Undisclosed"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2011","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quince Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Quince Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"PIF Partners","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"PIF Partners","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PIF Partners \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PIF Partners \/ Undisclosed"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Steroid","year":"2011","type":"Inapplicable","leadProduct":"Fluticasone Furoate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Sandoz B2B \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sandoz B2B \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Steroid","year":"2012","type":"Inapplicable","leadProduct":"Fluticasone Furoate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Assistance Publique \u2013 H\u00f4pitaux de Paris","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Assistance Publique \u2013 H\u00f4pitaux de Paris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ GSK"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Steroid","year":"2013","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Steroid","year":"2014","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Teva Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Viatris","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2013","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Viatris \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Viatris \/ Undisclosed"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Steroid","year":"2013","type":"Inapplicable","leadProduct":"Loteprednol Etabonate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Bausch & Lomb Incorporated \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bausch & Lomb Incorporated \/ Undisclosed"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Steroid","year":"2014","type":"Inapplicable","leadProduct":"Loteprednol Etabonate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Bausch & Lomb Incorporated \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bausch & Lomb Incorporated \/ Undisclosed"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Steroid","year":"2010","type":"Inapplicable","leadProduct":"Loteprednol Etabonate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Bausch & Lomb Incorporated \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bausch & Lomb Incorporated \/ Undisclosed"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Mapracorat","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Bausch & Lomb Incorporated \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bausch & Lomb Incorporated \/ Undisclosed"},{"orgOrder":0,"company":"Actavis Inc","sponsor":"Actavis Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Actavis Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Actavis Inc \/ Actavis Inc","highestDevelopmentStatusID":"10","companyTruncated":"Actavis Inc \/ Actavis Inc"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Sandoz B2B \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sandoz B2B \/ Undisclosed"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Sandoz B2B \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sandoz B2B \/ Undisclosed"},{"orgOrder":0,"company":"EMS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BRAZIL","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"EMS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"EMS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"EMS \/ Undisclosed"},{"orgOrder":0,"company":"EMS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BRAZIL","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"EMS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"EMS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"EMS \/ Undisclosed"},{"orgOrder":0,"company":"Padagis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Steroid","year":"2012","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Padagis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Padagis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Padagis \/ Undisclosed"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Novum Pharmaceutical Research Services","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2014","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Amneal Pharmaceuticals \/ Novum Pharmaceutical Research Services","highestDevelopmentStatusID":"10","companyTruncated":"Amneal Pharmaceuticals \/ Novum Pharmaceutical Research Services"},{"orgOrder":0,"company":"Organon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2019","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Organon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Organon \/ Undisclosed"},{"orgOrder":0,"company":"Organon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2019","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Organon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Organon \/ Undisclosed"},{"orgOrder":0,"company":"Organon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2019","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Organon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Organon \/ Undisclosed"},{"orgOrder":0,"company":"Organon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2019","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Organon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Organon \/ Undisclosed"},{"orgOrder":0,"company":"Organon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2019","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Organon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Organon \/ Undisclosed"},{"orgOrder":0,"company":"Eurofarma Laboratorios S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BRAZIL","productType":"Steroid","year":"2011","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Eurofarma Laboratorios S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eurofarma Laboratorios S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eurofarma Laboratorios S.A \/ Undisclosed"},{"orgOrder":0,"company":"Zheng Liu ENT","sponsor":"Zhejiang Xianju Pharmaceutical Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Zheng Liu ENT","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Zheng Liu ENT \/ Zhejiang Xianju Pharmaceutical Co., Ltd","highestDevelopmentStatusID":"10","companyTruncated":"Zheng Liu ENT \/ Zhejiang Xianju Pharmaceutical Co., Ltd"},{"orgOrder":0,"company":"Hamad Medical Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"QATAR","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Prednisolone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Hamad Medical Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hamad Medical Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hamad Medical Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Steroid","year":"2018","type":"Inapplicable","leadProduct":"Prednisone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Steroid","year":"2017","type":"Inapplicable","leadProduct":"Triamcinolone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Humanigen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Lenzilumab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Immunology","graph2":"Phase III","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Humanigen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Otilimab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Immunology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Otilimab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Immunology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Parexel","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Parexel"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Otilimab","moa":"||Granulocyte-macrophage colony-stimulating factor","graph1":"Immunology","graph2":"Phase III","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection, Pre-Filled","sponsorNew":"MorphoSys \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MorphoSys \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Otilimab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Immunology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"GSK \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ IQVIA"},{"orgOrder":0,"company":"GSK","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Otilimab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Immunology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"GSK \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ IQVIA"},{"orgOrder":0,"company":"GSK","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Otilimab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Immunology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"GSK \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ IQVIA"},{"orgOrder":0,"company":"GSK","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Otilimab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Immunology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"GSK \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ IQVIA"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Otilimab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Immunology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"MaaT013","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Undisclosed"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"MaaT013","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Undisclosed"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"MaaT013","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Undisclosed"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"MaaT013","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Undisclosed"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Skyepharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2022","type":"Partnership","leadProduct":"MaaT013","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ Skyepharma","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Skyepharma"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Bpifrance","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2020","type":"Series B Financing","leadProduct":"MaaT013","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.029999999999999999,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ Bpifrance","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Bpifrance"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Symbiosis Pharmaceutical Services","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2020","type":"Series B Financing","leadProduct":"MaaT013","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.02,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ Symbiosis Pharmaceutical Services","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Symbiosis Pharmaceutical Services"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"MaaT013","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Undisclosed"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"MaaT013","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Undisclosed"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"MaaT013","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Undisclosed"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"MaaT013","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Undisclosed"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"MaaT013","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Undisclosed"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"MaaT013","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Undisclosed"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"MaaT013","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Undisclosed"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"MaaT013","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Undisclosed"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"MaaT013","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Undisclosed"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"INRAE","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"MaaT013","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ INRAE","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ INRAE"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Clinigen Group","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2025","type":"Licensing Agreement","leadProduct":"MaaT013","moa":"||Gut microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.029999999999999999,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ Clinigen Group","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Clinigen Group"},{"orgOrder":0,"company":"Skyepharma","sponsor":"MaaT Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2022","type":"Partnership","leadProduct":"MaaT013","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"Skyepharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"Skyepharma \/ MaaT Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Skyepharma \/ MaaT Pharma"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"MaaT013","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Undisclosed"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"EIB","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2025","type":"Financing","leadProduct":"MaaT013","moa":"||Gut microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ EIB","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ EIB"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"IPP-201101","moa":"Heat shock cognate 71 kDa protein","graph1":"Immunology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Teva Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"IPP-201101","moa":"Heat shock cognate 71 kDa protein","graph1":"Immunology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Teva Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"ImmuPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Forigerimod","moa":"Heat shock cognate 71 kDa protein","graph1":"Immunology","graph2":"Phase III","graph3":"ImmuPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ImmuPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ImmuPharma \/ Undisclosed"},{"orgOrder":0,"company":"ImmuPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Forigerimod","moa":"Heat shock cognate 71 kDa protein","graph1":"Immunology","graph2":"Phase III","graph3":"ImmuPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ImmuPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ImmuPharma \/ Undisclosed"},{"orgOrder":0,"company":"ZevraDenmark","sponsor":"University of Kansas Medical Center | University College, London","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Arimoclomol Citrate","moa":"heat-shock protein inducers","graph1":"Immunology","graph2":"Phase III","graph3":"ZevraDenmark","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ZevraDenmark \/ University of Kansas Medical Center | University College, London","highestDevelopmentStatusID":"10","companyTruncated":"ZevraDenmark \/ University of Kansas Medical Center | University College, London"},{"orgOrder":0,"company":"ZevraDenmark","sponsor":"University of Kansas Medical Center | University College, London","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Arimoclomol Citrate","moa":"heat-shock protein inducers","graph1":"Immunology","graph2":"Phase III","graph3":"ZevraDenmark","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ZevraDenmark \/ University of Kansas Medical Center | University College, London","highestDevelopmentStatusID":"10","companyTruncated":"ZevraDenmark \/ University of Kansas Medical Center | University College, London"},{"orgOrder":0,"company":"University of Alberta","sponsor":"CSL Behring","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Human Immunoglobulin G","moa":"High affinity immunoglobulin gamma Fc receptor I; Putative high affinity immunoglobulin gamma Fc receptor IB; Low affinity immunoglobulin gamma Fc region receptor II-a; Low affinity immunoglobulin gamma Fc region receptor II-b; Low affinity immunoglobulin gamma Fc region receptor II-c; Low affinity immunoglobulin gamma Fc region receptor III-A; Low affinity immunoglobulin gamma Fc region receptor III-B; Complement C3; Complement C4-A; Complement C4-B; Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"University of Alberta","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University of Alberta \/ CSL Behring","highestDevelopmentStatusID":"10","companyTruncated":"University of Alberta \/ CSL Behring"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Human Immunoglobulin G","moa":"High affinity immunoglobulin gamma Fc receptor I; Putative high affinity immunoglobulin gamma Fc receptor IB; Low affinity immunoglobulin gamma Fc region receptor II-a; Low affinity immunoglobulin gamma Fc region receptor II-b; Low affinity immunoglobulin gamma Fc region receptor II-c; Low affinity immunoglobulin gamma Fc region receptor III-A; Low affinity immunoglobulin gamma Fc region receptor III-B; Complement C3; Complement C4-A; Complement C4-B; Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSL Behring \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CSL Behring \/ Undisclosed"},{"orgOrder":0,"company":"Octapharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Immune Globulin (Human)","moa":"High affinity immunoglobulin gamma Fc receptor I; Putative high affinity immunoglobulin gamma Fc receptor IB; Low affinity immunoglobulin gamma Fc region receptor II-a; Low affinity immunoglobulin gamma Fc region receptor II-b; Low affinity immunoglobulin gamma Fc region receptor II-c; Low affinity immunoglobulin gamma Fc region receptor III-A; Low affinity immunoglobulin gamma Fc region receptor III-B; Complement C3; Complement C4-A; Complement C4-B; Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Octapharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Octapharma \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"Efprezimod Alfa","moa":"High mobility group protein B1 | Heat shock 70 kDa protein 1A\/1B | Sialic acid-binding Ig-like lectin 10 | Heat shock protein HSP90","graph1":"Immunology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Laboratorios Silanes","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"MEXICO","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Desloratadine","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Laboratorios Silanes","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Laboratorios Silanes \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Laboratorios Silanes \/ Undisclosed"},{"orgOrder":0,"company":"Azidus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BRAZIL","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Loratadine","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Azidus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Azidus \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Azidus \/ Undisclosed"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Azelastine Hydrochloride","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Sandoz B2B \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sandoz B2B \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Azelastine Hydrochloride","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray, Metered","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Padagis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Azelastine Hydrochloride","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Padagis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Padagis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Padagis \/ Undisclosed"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Azelastine Hydrochloride","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Teva Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Yuhan Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Bilastine","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Yuhan Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Yuhan Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Yuhan Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Faes Farma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Bilastine","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Faes Farma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Faes Farma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Faes Farma \/ Undisclosed"},{"orgOrder":0,"company":"Organon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Desloratadine","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Organon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Organon \/ Undisclosed"},{"orgOrder":0,"company":"EMS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BRAZIL","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Desloratadine","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"EMS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"EMS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"EMS \/ Undisclosed"},{"orgOrder":0,"company":"EMS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BRAZIL","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Desloratadine","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"EMS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"EMS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"EMS \/ Undisclosed"},{"orgOrder":0,"company":"Eurofarma Laboratorios S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BRAZIL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Desloratadine","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Eurofarma Laboratorios S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eurofarma Laboratorios S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eurofarma Laboratorios S.A \/ Undisclosed"},{"orgOrder":0,"company":"Ache Laboratorios Farmaceuticos SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BRAZIL","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Diphenhydramine","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Ache Laboratorios Farmaceuticos SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Syrup","sponsorNew":"Ache Laboratorios Farmaceuticos SA \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ache Laboratorios Farmaceuticos SA \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Fexofenadine Hydrochloride","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Opella Healthcare Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Fexofenadine Hydrochloride","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Opella Healthcare Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Opella Healthcare Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Opella Healthcare Group \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Fexofenadine Hydrochloride","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Levocetirizine Dihydrochloride","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Zensei Pharmaceutical Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Levocetirizine Dihydrochloride","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"GSK \/ Zensei Pharmaceutical Co., Ltd.","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Zensei Pharmaceutical Co., Ltd."},{"orgOrder":0,"company":"Eurofarma Laboratorios S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BRAZIL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Levocetirizine Dihydrochloride","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Eurofarma Laboratorios S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Eurofarma Laboratorios S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eurofarma Laboratorios S.A \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Olopatadine Hydrochloride","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"Darvadstrocel","moa":"IFN-gamma","graph1":"Immunology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"CT-P39","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase III","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Ligelizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Ligelizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Ligelizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Ligelizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Ligelizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Ligelizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Ligelizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Ligelizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Ligelizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Ligelizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Ligelizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Ligelizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Ligelizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Ligelizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Ligelizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Omalizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Omalizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Omalizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Kashiv BioSciences","sponsor":"COD Research","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Omalizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase III","graph3":"Kashiv BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kashiv BioSciences \/ COD Research","highestDevelopmentStatusID":"10","companyTruncated":"Kashiv BioSciences \/ COD Research"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Omalizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Omalizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Omalizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Kashiv BioSciences","sponsor":"Amneal Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Licensing Agreement","leadProduct":"Omalizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase III","graph3":"Kashiv BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection, Pre-Filled","sponsorNew":"Kashiv BioSciences \/ Amneal Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Kashiv BioSciences \/ Amneal Pharmaceuticals"},{"orgOrder":0,"company":"Kashiv BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Omalizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase III","graph3":"Kashiv BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection, Pre-Filled","sponsorNew":"Kashiv BioSciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kashiv BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Kashiv BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Omalizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase III","graph3":"Kashiv BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection, Pre-Filled","sponsorNew":"Kashiv BioSciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kashiv BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Kashiv BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Omalizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase III","graph3":"Kashiv BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection, Pre-Filled","sponsorNew":"Kashiv BioSciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kashiv BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Genentech | Novartis Pharmaceuticals Corporation | Rho, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Omalizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase III","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Genentech | Novartis Pharmaceuticals Corporation | Rho, Inc","highestDevelopmentStatusID":"10","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ Genentech | Novartis Pharmaceuticals Corporation | Rho, Inc"},{"orgOrder":0,"company":"CSPC Baike","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"SYN008","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase III","graph3":"CSPC Baike","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CSPC Baike \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CSPC Baike \/ Undisclosed"},{"orgOrder":0,"company":"Probelte Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"House Dust Mite Allergoid","moa":"IgE","graph1":"Immunology","graph2":"Phase III","graph3":"Probelte Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Probelte Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Probelte Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"IBI311","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"IBI311","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"IBI311","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"IBI311","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"IBI311","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"IBI311","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"IBI311","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"IBI311","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"IBI311","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"VRDN-001","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Viridian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"VRDN-001","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Viridian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Minghui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"MHB018A","moa":"IGF-1\/IGF-2 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Minghui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Minghui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Minghui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Minghui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"MHB018A","moa":"IGF-1\/IGF-2 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Minghui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Minghui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Minghui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Minghui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"MHB018A","moa":"IGF-1\/IGF-2 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Minghui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Minghui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Minghui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Minghui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"MHB018A","moa":"IGF-1|IGF-2 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Minghui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Minghui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Minghui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Octapharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Octanorm","moa":"IgG","graph1":"Immunology","graph2":"Phase III","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Octapharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Octapharma \/ Undisclosed"},{"orgOrder":0,"company":"Assistance Publique \u2013 H\u00f4pitaux de Paris","sponsor":"CSL Behring | Association ASLUMARE","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Privigen","moa":"IgG","graph1":"Immunology","graph2":"Phase III","graph3":"Assistance Publique \u2013 H\u00f4pitaux de Paris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ CSL Behring | Association ASLUMARE","highestDevelopmentStatusID":"10","companyTruncated":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ CSL Behring | Association ASLUMARE"},{"orgOrder":0,"company":"Hanall Biopharma","sponsor":"Nona Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Batoclimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Hanall Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hanall Biopharma \/ Nona Biosciences","highestDevelopmentStatusID":"10","companyTruncated":"Hanall Biopharma \/ Nona Biosciences"},{"orgOrder":0,"company":"Hanall Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Batoclimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Hanall Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hanall Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hanall Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Immunovant","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Batoclimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Immunovant","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immunovant \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Immunovant \/ Undisclosed"},{"orgOrder":0,"company":"Immunovant","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Batoclimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Immunovant","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immunovant \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Immunovant \/ Undisclosed"},{"orgOrder":0,"company":"Immunovant","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Batoclimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Immunovant","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immunovant \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Immunovant \/ Undisclosed"},{"orgOrder":0,"company":"Immunovant","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Batoclimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Immunovant","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immunovant \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Immunovant \/ Undisclosed"},{"orgOrder":0,"company":"Immunovant","sponsor":"SVB Securities","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Public Offering","leadProduct":"Batoclimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Immunovant","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.080000000000000002,"dosageForm":"Injection","sponsorNew":"Immunovant \/ SVB Securities","highestDevelopmentStatusID":"10","companyTruncated":"Immunovant \/ SVB Securities"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"CSPC Pharmaceutical Group","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Agreement","leadProduct":"Batoclimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Nona Biosciences","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.14000000000000001,"dosageForm":"Injection","sponsorNew":"Nona Biosciences \/ CSPC Pharmaceutical Group","highestDevelopmentStatusID":"10","companyTruncated":"Nona Biosciences \/ CSPC Pharmaceutical Group"},{"orgOrder":0,"company":"Immunovant","sponsor":"Roivant Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Financing","leadProduct":"Batoclimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Immunovant","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.20000000000000001,"dosageForm":"Injection","sponsorNew":"Immunovant \/ Roivant Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Immunovant \/ Roivant Sciences"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Hudson Bay Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Series C Financing","leadProduct":"Batoclimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Nona Biosciences","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.10000000000000001,"dosageForm":"Injection","sponsorNew":"Nona Biosciences \/ Hudson Bay Capital","highestDevelopmentStatusID":"10","companyTruncated":"Nona Biosciences \/ Hudson Bay Capital"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Batoclimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nona Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nona Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Immunovant","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Batoclimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Immunovant","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immunovant \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Immunovant \/ Undisclosed"},{"orgOrder":0,"company":"Immunovant","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Batoclimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Immunovant","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immunovant \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Immunovant \/ Undisclosed"},{"orgOrder":0,"company":"Harbour BioMed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Batoclimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Harbour BioMed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Harbour BioMed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Harbour BioMed \/ Undisclosed"},{"orgOrder":0,"company":"Harbour BioMed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Batoclimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Harbour BioMed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Harbour BioMed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Harbour BioMed \/ Undisclosed"},{"orgOrder":0,"company":"Immunovant","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Batoclimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Immunovant","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immunovant \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Immunovant \/ Undisclosed"},{"orgOrder":0,"company":"Immunovant","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Batoclimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Immunovant","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immunovant \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Immunovant \/ Undisclosed"},{"orgOrder":0,"company":"Immunovant","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Batoclimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Immunovant","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immunovant \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Immunovant \/ Undisclosed"},{"orgOrder":0,"company":"Immunovant","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Batoclimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Immunovant","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immunovant \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Immunovant \/ Undisclosed"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Batoclimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nona Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nona Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Batoclimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nona Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nona Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Batoclimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nona Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nona Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Immunovant","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Batoclimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Immunovant","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immunovant \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Immunovant \/ Undisclosed"},{"orgOrder":0,"company":"Argenx","sponsor":"Quintiles Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Argenx \/ Quintiles Inc","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Quintiles Inc"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"Argenx","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Argenx \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ IQVIA"},{"orgOrder":0,"company":"Argenx","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Argenx \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ IQVIA"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"Clinique Neuro-Outaouais","sponsor":"Argenx","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Clinique Neuro-Outaouais","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Clinique Neuro-Outaouais \/ Argenx","highestDevelopmentStatusID":"10","companyTruncated":"Clinique Neuro-Outaouais \/ Argenx"},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Collaboration","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Halozyme Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Halozyme Therapeutics \/ Argenx","highestDevelopmentStatusID":"10","companyTruncated":"Halozyme Therapeutics \/ Argenx"},{"orgOrder":0,"company":"Harbour BioMed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"HBM9161","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Harbour BioMed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Harbour BioMed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Harbour BioMed \/ Undisclosed"},{"orgOrder":0,"company":"Harbour BioMed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"HBM9161","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Harbour BioMed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Harbour BioMed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Harbour BioMed \/ Undisclosed"},{"orgOrder":0,"company":"Harbour BioMed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"HBM9161","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Harbour BioMed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Harbour BioMed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Harbour BioMed \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Nipocalimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Nipocalimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Nipocalimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Nipocalimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Nipocalimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Nipocalimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Nipocalimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Nipocalimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Nipocalimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Nipocalimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Nipocalimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Nipocalimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Nipocalimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Rozanolixizumab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Rozanolixizumab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Rozanolixizumab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Rozanolixizumab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"AK111","moa":"IL-17A receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"AK111","moa":"IL-17A receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"AB2 Bio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2020","type":"Collaboration","leadProduct":"Tadekinig Alpha","moa":"IL-18 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"WuXi Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"WuXi Biologics \/ AB2 Bio","highestDevelopmentStatusID":"10","companyTruncated":"WuXi Biologics \/ AB2 Bio"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Icotrokinra","moa":"IL23R","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Icotrokinra","moa":"IL23R","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"ALK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Plant Extract\/Herbal","year":"2019","type":"Inapplicable","leadProduct":"Allergen Extract","moa":"IL-4 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ALK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ALK \/ Undisclosed"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"CM310","moa":"IL-4 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connoya Biomedical Technology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Connoya Biomedical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"CM310","moa":"IL-4 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connoya Biomedical Technology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Connoya Biomedical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Biocad","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"RUSSIA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"BCD-085","moa":"IL-6 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Biocad","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocad \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biocad \/ Undisclosed"},{"orgOrder":0,"company":"Biocad","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"RUSSIA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"BCD-085","moa":"IL-6 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Biocad","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocad \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biocad \/ Undisclosed"},{"orgOrder":0,"company":"Biocad","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"RUSSIA","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"BCD-085","moa":"IL-6 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Biocad","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocad \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biocad \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"CT-P47","moa":"IL-6-alpha receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Satralizumab","moa":"IL6Ralpha\/GP130","graph1":"Immunology","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chugai Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Satralizumab","moa":"IL6Ralpha\/GP130","graph1":"Immunology","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chugai Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Satralizumab","moa":"IL6Ralpha\/GP130","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Satralizumab","moa":"IL6Ralpha\/GP130","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Satralizumab","moa":"IL6Ralpha\/GP130","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Satralizumab","moa":"IL6Ralpha\/GP130","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"FCR001","moa":"Immune tolerance","graph1":"Immunology","graph2":"Phase III","graph3":"Talaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Talaris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Talaris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2012","type":"Inapplicable","leadProduct":"FCR001","moa":"Immune tolerance","graph1":"Immunology","graph2":"Phase III","graph3":"Talaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Talaris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Talaris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"FCR001","moa":"Immune tolerance","graph1":"Immunology","graph2":"Phase III","graph3":"Talaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Talaris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Talaris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"FCR001","moa":"Immune tolerance","graph1":"Immunology","graph2":"Phase III","graph3":"Talaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Talaris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Talaris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"FCR001","moa":"Immune tolerance","graph1":"Immunology","graph2":"Phase III","graph3":"Talaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Talaris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Talaris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"FCR001","moa":"Immune tolerance","graph1":"Immunology","graph2":"Phase III","graph3":"Talaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Talaris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Talaris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Public Offering","leadProduct":"FCR001","moa":"Immune tolerance","graph1":"Immunology","graph2":"Phase III","graph3":"Talaris Therapeutics","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.14999999999999999,"dosageForm":"Infusion","sponsorNew":"Talaris Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"10","companyTruncated":"Talaris Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Surveyor Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Series B Financing","leadProduct":"FCR001","moa":"Immune tolerance","graph1":"Immunology","graph2":"Phase III","graph3":"Talaris Therapeutics","amount2":0.12,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.12,"dosageForm":"Infusion","sponsorNew":"Talaris Therapeutics \/ Surveyor Capital","highestDevelopmentStatusID":"10","companyTruncated":"Talaris Therapeutics \/ Surveyor Capital"},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"FCR001","moa":"Immune tolerance","graph1":"Immunology","graph2":"Phase III","graph3":"Talaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Talaris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Talaris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"FCR001","moa":"Immune tolerance","graph1":"Immunology","graph2":"Phase III","graph3":"Talaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Talaris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Talaris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"FCR001","moa":"Immune tolerance","graph1":"Immunology","graph2":"Phase III","graph3":"Talaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Talaris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Talaris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"FCR001","moa":"Immune tolerance","graph1":"Immunology","graph2":"Phase III","graph3":"Talaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Talaris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Talaris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"FCR001","moa":"Immune tolerance","graph1":"Immunology","graph2":"Phase III","graph3":"Talaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Talaris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Talaris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"FCR001","moa":"Immune tolerance","graph1":"Immunology","graph2":"Phase III","graph3":"Talaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Talaris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Talaris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"FCR001","moa":"Immune tolerance","graph1":"Immunology","graph2":"Phase III","graph3":"Talaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Talaris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Talaris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Medeor Therapeutics","sponsor":"California Institute for Regenerative Medicine (CIRM)","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"MDR-101","moa":"Immune tolerance","graph1":"Immunology","graph2":"Phase III","graph3":"Medeor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medeor Therapeutics \/ California Institute for Regenerative Medicine (CIRM)","highestDevelopmentStatusID":"10","companyTruncated":"Medeor Therapeutics \/ California Institute for Regenerative Medicine (CIRM)"},{"orgOrder":0,"company":"Medeor Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"MDR-101","moa":"Immune tolerance","graph1":"Immunology","graph2":"Phase III","graph3":"Medeor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medeor Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Medeor Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Medeor Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"MDR-101","moa":"Immune tolerance","graph1":"Immunology","graph2":"Phase III","graph3":"Medeor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medeor Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Medeor Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Medeor Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"MDR-101","moa":"Immune tolerance","graph1":"Immunology","graph2":"Phase III","graph3":"Medeor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medeor Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Medeor Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Medeor Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"MDR-101","moa":"Immune tolerance","graph1":"Immunology","graph2":"Phase III","graph3":"Medeor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medeor Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Medeor Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Medeor Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"MDR-101","moa":"Immune tolerance","graph1":"Immunology","graph2":"Phase III","graph3":"Medeor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medeor Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Medeor Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ImmuPharma","sponsor":"Avion Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2020","type":"Agreement","leadProduct":"Rigerimod","moa":"Immuno","graph1":"Immunology","graph2":"Phase III","graph3":"ImmuPharma","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"ImmuPharma \/ Avion Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"ImmuPharma \/ Avion Pharmaceuticals"},{"orgOrder":0,"company":"SK Plasma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Liv-Gamma SN","moa":"Immunoglobulins","graph1":"Immunology","graph2":"Phase III","graph3":"SK Plasma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SK Plasma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SK Plasma \/ Undisclosed"},{"orgOrder":0,"company":"SK Plasma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2017","type":"Inapplicable","leadProduct":"Liv-Gamma SN","moa":"Immunoglobulins","graph1":"Immunology","graph2":"Phase III","graph3":"SK Plasma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SK Plasma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SK Plasma \/ Undisclosed"},{"orgOrder":0,"company":"ImmuPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"IPP-201101","moa":"immunomodulators","graph1":"Immunology","graph2":"Phase III","graph3":"ImmuPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmuPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ImmuPharma \/ Undisclosed"},{"orgOrder":0,"company":"ImmuPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"IPP-201101","moa":"immunomodulators","graph1":"Immunology","graph2":"Phase III","graph3":"ImmuPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmuPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ImmuPharma \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibiotic","year":"2013","type":"Inapplicable","leadProduct":"Mycophenolate Mofetil","moa":"Inosine-5'-monophosphate dehydrogenase (IMPDH)","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Mycophenolate Mofetil","moa":"Inosine-5'-monophosphate dehydrogenase (IMPDH)","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Ypsomed","sponsor":"Viridian Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Agreement","leadProduct":"Veligrotug","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Ypsomed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ypsomed \/ Viridian Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Ypsomed \/ Viridian Therapeutics"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Veligrotug","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Viridian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Veligrotug","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Viridian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Veligrotug","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Viridian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Public Offering","leadProduct":"Veligrotug","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0.17000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"Viridian Therapeutics \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Public Offering","leadProduct":"Veligrotug","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0.23000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"Viridian Therapeutics \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Veligrotug","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Viridian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Veligrotug","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Viridian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Veligrotug","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Viridian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Veligrotug","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Viridian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Veligrotug","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Viridian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Veligrotug","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Viridian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Public Offering","leadProduct":"Veligrotug","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"Viridian Therapeutics \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Veligrotug","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Viridian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Fairmount Funds Management LLC","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Private Placement","leadProduct":"Veligrotug","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0.19,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.19,"dosageForm":"Infusion","sponsorNew":"Viridian Therapeutics \/ Fairmount Funds Management LLC","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Fairmount Funds Management LLC"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Financing","leadProduct":"Veligrotug","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Viridian Therapeutics \/ Hercules Capital","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Hercules Capital"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Veligrotug","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Viridian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Veligrotug","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Viridian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Public Offering","leadProduct":"Veligrotug","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0.27000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"Viridian Therapeutics \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Public Offering","leadProduct":"Veligrotug","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"Viridian Therapeutics \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Polpharma Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"POLAND","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Phase III","graph3":"Polpharma Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Polpharma Biologics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Polpharma Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Alvotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Phase III","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alvotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/ Undisclosed"},{"orgOrder":0,"company":"Polpharma Biologics","sponsor":"Fresenius Kabi AG","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"POLAND","productType":"Antibody, Unconjugated","year":"2025","type":"Licensing Agreement","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Phase III","graph3":"Polpharma Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Polpharma Biologics \/ Fresenius Kabi AG","highestDevelopmentStatusID":"10","companyTruncated":"Polpharma Biologics \/ Fresenius Kabi AG"},{"orgOrder":0,"company":"Polpharma Biologics","sponsor":"MS Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"POLAND","productType":"Antibody, Unconjugated","year":"2025","type":"Licensing Agreement","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Phase III","graph3":"Polpharma Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Polpharma Biologics \/ MS Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Polpharma Biologics \/ MS Pharma"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Etrolizumab","moa":"Integrin beta-7","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Etrolizumab","moa":"Integrin beta-7","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Etrolizumab","moa":"Integrin beta-7","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||Integrin beta-7","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||Integrin beta-7","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Etrolizumab","moa":"Integrin beta-7","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Etrolizumab","moa":"Integrin beta-7","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Etrolizumab","moa":"Integrin beta-7","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Etrolizumab","moa":"Integrin beta-7","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Etrolizumab","moa":"Integrin beta-7","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Alvotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"AVT16","moa":"Integrin-alpha-4\/beta-7","graph1":"Immunology","graph2":"Phase III","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alvotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/ Undisclosed"},{"orgOrder":0,"company":"Polpharma Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"POLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"PB016","moa":"Integrin-alpha-4\/beta-7","graph1":"Immunology","graph2":"Phase III","graph3":"Polpharma Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Polpharma Biologics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Polpharma Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Dazukibart","moa":"Interferon beta","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Emapalumab","moa":"Interferon gamma","graph1":"Immunology","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Orphan Biovitrum AB \/ Undisclosed"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Emapalumab","moa":"Interferon gamma","graph1":"Immunology","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Orphan Biovitrum AB \/ Undisclosed"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Emapalumab","moa":"Interferon gamma","graph1":"Immunology","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Orphan Biovitrum AB \/ Undisclosed"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Emapalumab","moa":"Interferon gamma","graph1":"Immunology","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Orphan Biovitrum AB \/ Undisclosed"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Emapalumab","moa":"Interferon gamma","graph1":"Immunology","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Orphan Biovitrum AB \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Anifrolumab","moa":"Interferon-alpha\/beta receptor alpha chain","graph1":"Immunology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Parexel","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Parexel"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Anifrolumab","moa":"Interferon-alpha\/beta receptor alpha chain","graph1":"Immunology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Anifrolumab","moa":"Interferon-alpha\/beta receptor alpha chain","graph1":"Immunology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"MEDI-546","moa":"Interferon-alpha\/beta receptor alpha chain","graph1":"Immunology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ IQVIA"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"MEDI-546","moa":"Interferon-alpha\/beta receptor alpha chain","graph1":"Immunology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ MedImmune","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ MedImmune"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Ixekizumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Ixekizumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Ixekizumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Ixekizumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"SHR-1314","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase III","graph3":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Suzhou Suncadia Biopharmaceuticals Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Suzhou Suncadia Biopharmaceuticals Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"SHR-1314","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase III","graph3":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Suzhou Suncadia Biopharmaceuticals Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Suzhou Suncadia Biopharmaceuticals Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Canakinumab","moa":"Interleukin-1 beta","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Canakinumab","moa":"Interleukin-1 beta","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"PRINTO\/PRCSG","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Canakinumab","moa":"Interleukin-1 beta","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ PRINTO\/PRCSG","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ PRINTO\/PRCSG"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Canakinumab","moa":"Interleukin-1 beta","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"CMIC Co, Ltd. Japan","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Anakinra","moa":"Interleukin-1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ CMIC Co, Ltd. Japan","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Orphan Biovitrum AB \/ CMIC Co, Ltd. Japan"},{"orgOrder":0,"company":"Belgian Inflammatory Bowel Disease Research and Development","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Immunology","graph2":"Phase III","graph3":"Belgian Inflammatory Bowel Disease Research and Development","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Belgian Inflammatory Bowel Disease Research and Development \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Belgian Inflammatory Bowel Disease Research and Development \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Belgian Inflammatory Bowel Disease Research and Development","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Immunology","graph2":"Phase III","graph3":"Belgian Inflammatory Bowel Disease Research and Development","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Belgian Inflammatory Bowel Disease Research and Development \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Belgian Inflammatory Bowel Disease Research and Development \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Janssen-Cilag","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ITALY","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Immunology","graph2":"Phase III","graph3":"Janssen-Cilag","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Janssen-Cilag \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Janssen-Cilag \/ Undisclosed"},{"orgOrder":0,"company":"Janssen-Cilag","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ITALY","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Immunology","graph2":"Phase III","graph3":"Janssen-Cilag","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Janssen-Cilag \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Janssen-Cilag \/ Undisclosed"},{"orgOrder":0,"company":"Alvotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Immunology","graph2":"Phase III","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Brodalumab","moa":"Interleukin-17 receptor A","graph1":"Immunology","graph2":"Phase III","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kyowa Kirin \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kyowa Kirin \/ Undisclosed"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Brodalumab","moa":"Interleukin-17 receptor A","graph1":"Immunology","graph2":"Phase III","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kyowa Kirin \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kyowa Kirin \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Brodalumab","moa":"Interleukin-17 receptor A||Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Brodalumab","moa":"Interleukin-17 receptor A","graph1":"Immunology","graph2":"Phase III","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kyowa Kirin \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kyowa Kirin \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Brodalumab","moa":"Interleukin-17 receptor A","graph1":"Immunology","graph2":"Phase III","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Brodalumab","moa":"Interleukin-17 receptor A","graph1":"Immunology","graph2":"Phase III","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Sonelokimab","moa":"Interleukin-17F | Interleukin 17A","graph1":"Immunology","graph2":"Phase III","graph3":"MoonLake Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MoonLake Immunotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MoonLake Immunotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Sonelokimab","moa":"Interleukin-17F | Interleukin 17A","graph1":"Immunology","graph2":"Phase III","graph3":"MoonLake Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MoonLake Immunotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MoonLake Immunotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Sonelokimab","moa":"Interleukin-17F | Interleukin 17A","graph1":"Immunology","graph2":"Phase III","graph3":"MoonLake Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MoonLake Immunotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MoonLake Immunotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Sonelokimab","moa":"Interleukin-17F | Interleukin 17A","graph1":"Immunology","graph2":"Phase III","graph3":"MoonLake Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MoonLake Immunotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MoonLake Immunotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Sonelokimab","moa":"Interleukin-17F | Interleukin 17A","graph1":"Immunology","graph2":"Phase III","graph3":"MoonLake Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MoonLake Immunotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MoonLake Immunotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Sonelokimab","moa":"Interleukin-17F | Interleukin 17A","graph1":"Immunology","graph2":"Phase III","graph3":"MoonLake Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MoonLake Immunotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MoonLake Immunotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Sonelokimab","moa":"Interleukin-17F | Interleukin 17A","graph1":"Immunology","graph2":"Phase III","graph3":"MoonLake Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MoonLake Immunotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MoonLake Immunotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"SVB Securities","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Public Offering","leadProduct":"Sonelokimab","moa":"Interleukin-17F | Interleukin 17A","graph1":"Immunology","graph2":"Phase III","graph3":"MoonLake Immunotherapeutics","amount2":0.25,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.25,"dosageForm":"Injection","sponsorNew":"MoonLake Immunotherapeutics \/ SVB Securities","highestDevelopmentStatusID":"10","companyTruncated":"MoonLake Immunotherapeutics \/ SVB Securities"},{"orgOrder":0,"company":"AB2 Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Tadekinig Alfa","moa":"Interleukin-18","graph1":"Immunology","graph2":"Phase III","graph3":"AB2 Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AB2 Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AB2 Bio \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Brazikumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Brazikumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Brazikumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Brazikumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ AbbVie Inc","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ AbbVie Inc"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Termination","leadProduct":"Brazikumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Phase III","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan Aesthetics \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Allergan Aesthetics \/ AstraZeneca"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Acquisition","leadProduct":"Brazikumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Phase III","graph3":"Allergan Aesthetics","amount2":63,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":63,"dosageForm":"Undisclosed","sponsorNew":"Allergan Aesthetics \/ AbbVie Inc","highestDevelopmentStatusID":"10","companyTruncated":"Allergan Aesthetics \/ AbbVie Inc"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Divestment","leadProduct":"Brazikumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Phase III","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan Aesthetics \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Allergan Aesthetics \/ AstraZeneca"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Janssen-Cilag","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ITALY","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Phase III","graph3":"Janssen-Cilag","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Janssen-Cilag \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Janssen-Cilag \/ Undisclosed"},{"orgOrder":0,"company":"Janssen-Cilag","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ITALY","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Phase III","graph3":"Janssen-Cilag","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Janssen-Cilag \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Janssen-Cilag \/ Undisclosed"},{"orgOrder":0,"company":"University of Pennsylvania","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Phase III","graph3":"University of Pennsylvania","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of Pennsylvania \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"10","companyTruncated":"University of Pennsylvania \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson \/ AbbVie Inc","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ AbbVie Inc"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Benralizumab","moa":"Interleukin-5 receptor subunit alpha","graph1":"Immunology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Icon Plc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Clazakizumab","moa":"Interleukin-6","graph1":"Immunology","graph2":"Phase III","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSL Behring \/ Icon Plc","highestDevelopmentStatusID":"10","companyTruncated":"CSL Behring \/ Icon Plc"},{"orgOrder":0,"company":"Vitaeris","sponsor":"CSL","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2020","type":"Acquisition","leadProduct":"Clazakizumab","moa":"Interleukin-6","graph1":"Immunology","graph2":"Phase III","graph3":"Vitaeris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vitaeris \/ CSL","highestDevelopmentStatusID":"10","companyTruncated":"Vitaeris \/ CSL"},{"orgOrder":0,"company":"R-Pharm","sponsor":"IQVIA | Thermo Fisher Scientific","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"RUSSIA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Olokizumab","moa":"Interleukin-6","graph1":"Immunology","graph2":"Phase III","graph3":"R-Pharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"R-Pharm \/ IQVIA | Thermo Fisher Scientific","highestDevelopmentStatusID":"10","companyTruncated":"R-Pharm \/ IQVIA | Thermo Fisher Scientific"},{"orgOrder":0,"company":"R-Pharm","sponsor":"Quintiles Inc | OCT Clinical Trials | Mene Research","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"RUSSIA","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Olokizumab","moa":"Interleukin-6","graph1":"Immunology","graph2":"Phase III","graph3":"R-Pharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"R-Pharm \/ Quintiles Inc | OCT Clinical Trials | Mene Research","highestDevelopmentStatusID":"10","companyTruncated":"R-Pharm \/ Quintiles Inc | OCT Clinical Trials | Mene Research"},{"orgOrder":0,"company":"R-Pharm","sponsor":"Quintiles Inc | OCT Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"RUSSIA","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Olokizumab","moa":"Interleukin-6","graph1":"Immunology","graph2":"Phase III","graph3":"R-Pharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"R-Pharm \/ Quintiles Inc | OCT Clinical Trials","highestDevelopmentStatusID":"10","companyTruncated":"R-Pharm \/ Quintiles Inc | OCT Clinical Trials"},{"orgOrder":0,"company":"R-Pharm","sponsor":"Quintiles Inc | OCT Clinical Trials | Mene Research","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"RUSSIA","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Olokizumab","moa":"Interleukin-6","graph1":"Immunology","graph2":"Phase III","graph3":"R-Pharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"R-Pharm \/ Quintiles Inc | OCT Clinical Trials | Mene Research","highestDevelopmentStatusID":"10","companyTruncated":"R-Pharm \/ Quintiles Inc | OCT Clinical Trials | Mene Research"},{"orgOrder":0,"company":"R-Pharm","sponsor":"IQVIA | OCT Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"RUSSIA","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Olokizumab","moa":"Interleukin-6","graph1":"Immunology","graph2":"Phase III","graph3":"R-Pharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"R-Pharm \/ IQVIA | OCT Clinical Trials","highestDevelopmentStatusID":"10","companyTruncated":"R-Pharm \/ IQVIA | OCT Clinical Trials"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Sirukumab","moa":"Interleukin-6","graph1":"Immunology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Sirukumab","moa":"Interleukin-6","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ GSK"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Sirukumab","moa":"Interleukin-6","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ GSK"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Sirukumab","moa":"Interleukin-6","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ GSK"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Sirukumab","moa":"Interleukin-6","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Sirukumab","moa":"Interleukin-6","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ GSK"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"BAT1806","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio-Thera Solutions \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"BAT1806","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio-Thera Solutions \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Biocad","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"RUSSIA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"BCD-089","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase III","graph3":"Biocad","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biocad \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biocad \/ Undisclosed"},{"orgOrder":0,"company":"Biocad","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"RUSSIA","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"BCD-089","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase III","graph3":"Biocad","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biocad \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biocad \/ Undisclosed"},{"orgOrder":0,"company":"Biocad","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"RUSSIA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Levilimab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase III","graph3":"Biocad","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biocad \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biocad \/ Undisclosed"},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"MSB11456","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase III","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fresenius Kabi AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Fresenius Kabi AG \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"SAR153191","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"SAR153191","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"SAR153191","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"JW Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase III","graph3":"JW Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"JW Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"JW Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"JW Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase III","graph3":"JW Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"JW Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"JW Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chugai Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chugai Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Assistance Publique \u2013 H\u00f4pitaux de Paris","sponsor":"Chugai Pharmaceutical | F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase III","graph3":"Assistance Publique \u2013 H\u00f4pitaux de Paris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Chugai Pharmaceutical | F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Chugai Pharmaceutical | F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Generium","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"RUSSIA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase III","graph3":"Generium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Generium \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Generium \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Alloksys Life Sciences","sponsor":"Aix Scientifics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Enzyme","year":"2010","type":"Inapplicable","leadProduct":"Bovine Intestinal Alkaline Phosphatase","moa":"Intestinal alkaline phosphatase","graph1":"Immunology","graph2":"Phase III","graph3":"Alloksys Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alloksys Life Sciences \/ Aix Scientifics","highestDevelopmentStatusID":"10","companyTruncated":"Alloksys Life Sciences \/ Aix Scientifics"},{"orgOrder":0,"company":"EA Pharma","sponsor":"Kissei Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Carotegrast Methyl","moa":"Alpha-4 integrin||ITGA4\/ITGB1","graph1":"Immunology","graph2":"Phase III","graph3":"EA Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"EA Pharma \/ Kissei Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"EA Pharma \/ Kissei Pharmaceutical"},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"EA Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Carotegrast Methyl","moa":"ITGA4\/ITGB1","graph1":"Immunology","graph2":"Phase III","graph3":"Kissei Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Kissei Pharmaceutical \/ EA Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Kissei Pharmaceutical \/ EA Pharma"},{"orgOrder":0,"company":"Reistone Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ivarmacitinib","moa":"JAK1||Janus kinase 1 (JAK-1)","graph1":"Immunology","graph2":"Phase III","graph3":"Reistone Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Reistone Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Reistone Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Reistone Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Ivarmacitinib","moa":"JAK1||Janus kinase 1 (JAK-1)","graph1":"Immunology","graph2":"Phase III","graph3":"Reistone Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Reistone Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Reistone Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Ivarmacitinib","moa":"JAK1||Janus kinase 1 (JAK-1)","graph1":"Immunology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ivarmacitinib","moa":"JAK1||Janus kinase 1 (JAK-1)","graph1":"Immunology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ivarmacitinib","moa":"JAK1||Janus kinase 1 (JAK-1)","graph1":"Immunology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ivarmacitinib","moa":"JAK1||Janus kinase 1 (JAK-1)","graph1":"Immunology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ivarmacitinib","moa":"JAK1||Janus kinase 1 (JAK-1)","graph1":"Immunology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ivarmacitinib","moa":"JAK1||Janus kinase 1 (JAK-1)","graph1":"Immunology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ivarmacitinib","moa":"JAK1||Janus kinase 1 (JAK-1)","graph1":"Immunology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ivarmacitinib","moa":"JAK1||Janus kinase 1 (JAK-1)","graph1":"Immunology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ivarmacitinib","moa":"JAK1||Janus kinase 1 (JAK-1)","graph1":"Immunology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"LNK01001","moa":"JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Lynk Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lynk Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lynk Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"LNK01001","moa":"JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Lynk Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lynk Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lynk Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"LNK01001","moa":"JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Lynk Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lynk Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lynk Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"LNK01001","moa":"JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Lynk Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lynk Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lynk Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"China Grand Prosperity Investment","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Series C Financing","leadProduct":"LNK01001","moa":"JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Lynk Pharmaceuticals","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.040000000000000001,"dosageForm":"Capsule","sponsorNew":"Lynk Pharmaceuticals \/ China Grand Prosperity Investment","highestDevelopmentStatusID":"10","companyTruncated":"Lynk Pharmaceuticals \/ China Grand Prosperity Investment"},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"China Grand Prosperity Investment","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Series C Financing","leadProduct":"LNK01001","moa":"JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Lynk Pharmaceuticals","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.040000000000000001,"dosageForm":"Capsule","sponsorNew":"Lynk Pharmaceuticals \/ China Grand Prosperity Investment","highestDevelopmentStatusID":"10","companyTruncated":"Lynk Pharmaceuticals \/ China Grand Prosperity Investment"},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"LNK01001","moa":"JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Lynk Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lynk Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lynk Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"Jiangsu Simcere Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Partnership","leadProduct":"LNK01001","moa":"JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Lynk Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lynk Pharmaceuticals \/ Jiangsu Simcere Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Lynk Pharmaceuticals \/ Jiangsu Simcere Pharmaceutical"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Rovadicitinib","moa":"JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"JIANGSU VCARE PHARMATECH CO., LTD","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"VC005","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"JIANGSU VCARE PHARMATECH CO., LTD","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"JIANGSU VCARE PHARMATECH CO., LTD \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"JIANGSU VCARE PHARMATECH CO., LTD \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Zelgen Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Jaktinib","moa":"JAK1\/JAK2","graph1":"Immunology","graph2":"Phase III","graph3":"Suzhou Zelgen Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Zelgen Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Jaktinib","moa":"JAK1\/JAK2","graph1":"Immunology","graph2":"Phase III","graph3":"Suzhou Zelgen Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Peficitinib","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Peficitinib","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Peficitinib","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Peficitinib","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Peficitinib","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Peficitinib","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Peficitinib","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"JANSSEN BIOTECH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Peficitinib","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ JANSSEN BIOTECH","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ JANSSEN BIOTECH"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Peficitinib","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Globe Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BANGLADESH","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase III","graph3":"Globe Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Globe Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Globe Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"KIT","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celldex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"KIT","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celldex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Public Offering","leadProduct":"Barzolvolimab","moa":"KIT","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0.46000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.46000000000000002,"dosageForm":"Injection","sponsorNew":"Celldex Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Leerink Partners"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"KIT","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celldex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"KIT","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celldex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"KIT","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celldex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"KIT","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celldex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"KIT","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celldex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"KIT","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celldex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"KIT","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celldex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Public Offering","leadProduct":"Barzolvolimab","moa":"KIT","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0.25,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.46000000000000002,"dosageForm":"Injection","sponsorNew":"Celldex Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Leerink Partners"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Public Offering","leadProduct":"Barzolvolimab","moa":"KIT","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0.40000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.46000000000000002,"dosageForm":"Injection","sponsorNew":"Celldex Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Leerink Partners"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"KIT","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celldex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"KIT","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celldex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"KIT","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celldex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"KIT","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celldex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Public Offering","leadProduct":"Barzolvolimab","moa":"KIT","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0.25,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.25,"dosageForm":"Injection","sponsorNew":"Celldex Therapeutics \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"KIT","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celldex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"KIT","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celldex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"KIT","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celldex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"LianBio","sponsor":"NImmune Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"Omilancor","moa":"LANCL2\/MAP2K6","graph1":"Immunology","graph2":"Phase III","graph3":"LianBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"LianBio \/ NImmune Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"LianBio \/ NImmune Biopharma"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Blood and Marrow Transplant Clinical Trials Network | National Institutes of Health | National Heart, Lung, and Blood Institute | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"Alpha 1-Antitrypsin","moa":"Leukocyte elastase","graph1":"Immunology","graph2":"Phase III","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSL Behring \/ Blood and Marrow Transplant Clinical Trials Network | National Institutes of Health | National Heart, Lung, and Blood Institute | National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"CSL Behring \/ Blood and Marrow Transplant Clinical Trials Network | National Institutes of Health | National Heart, Lung, and Blood Institute | National Cancer Institute"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Nomacopan","moa":"Leukotriene B4 receptor | Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akari Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Akari Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"Nomacopan","moa":"Leukotriene B4 receptor | Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akari Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Akari Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Nomacopan","moa":"Leukotriene B4 receptor | Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akari Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Akari Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Nomacopan","moa":"Leukotriene B4 receptor | Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akari Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Akari Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Nomacopan","moa":"||Leukotriene B4 receptor | Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akari Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Akari Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Nomacopan","moa":"Leukotriene B4 receptor | Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akari Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Akari Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Nomacopan","moa":"Leukotriene B4 receptor | Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akari Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Akari Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Nomacopan","moa":"Leukotriene B4 receptor | Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akari Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Akari Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Nomacopan","moa":"Leukotriene B4 receptor | Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akari Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Akari Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Nomacopan","moa":"Leukotriene B4 receptor | Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akari Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Akari Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Nomacopan","moa":"Leukotriene B4 receptor | Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akari Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Akari Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Zenas BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Obexelimab","moa":"Low affinity immunoglobulin gamma Fc region receptor II-b | B-lymphocyte antigen CD19","graph1":"Immunology","graph2":"Phase III","graph3":"Zenas BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Zenas BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zenas BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Zenas BioPharma","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Collaboration","leadProduct":"Obexelimab","moa":"Low affinity immunoglobulin gamma Fc region receptor II-b | B-lymphocyte antigen CD19","graph1":"Immunology","graph2":"Phase III","graph3":"Zenas BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Zenas BioPharma \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Zenas BioPharma \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Zenas BioPharma","sponsor":"Enavate Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Series B Financing","leadProduct":"Obexelimab","moa":"Low affinity immunoglobulin gamma Fc region receptor II-b | B-lymphocyte antigen CD19","graph1":"Immunology","graph2":"Phase III","graph3":"Zenas BioPharma","amount2":0.12,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.12,"dosageForm":"Infusion","sponsorNew":"Zenas BioPharma \/ Enavate Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Zenas BioPharma \/ Enavate Sciences"},{"orgOrder":0,"company":"Zenas BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Obexelimab","moa":"Low affinity immunoglobulin gamma Fc region receptor II-b | B-lymphocyte antigen CD19","graph1":"Immunology","graph2":"Phase III","graph3":"Zenas BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Zenas BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zenas BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Zenas BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Obexelimab","moa":"Low affinity immunoglobulin gamma Fc region receptor II-b | B-lymphocyte antigen CD19","graph1":"Immunology","graph2":"Phase III","graph3":"Zenas BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Zenas BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zenas BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Zenas BioPharma","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Public Offering","leadProduct":"Obexelimab","moa":"Low affinity immunoglobulin gamma Fc region receptor II-b | B-lymphocyte antigen CD19","graph1":"Immunology","graph2":"Phase III","graph3":"Zenas BioPharma","amount2":0.23000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.26000000000000001,"dosageForm":"Infusion","sponsorNew":"Zenas BioPharma \/ Morgan Stanley","highestDevelopmentStatusID":"10","companyTruncated":"Zenas BioPharma \/ Morgan Stanley"},{"orgOrder":0,"company":"Zenas BioPharma","sponsor":"SR One Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Series C Financing","leadProduct":"Obexelimab","moa":"Low affinity immunoglobulin gamma Fc region receptor II-b | B-lymphocyte antigen CD19","graph1":"Immunology","graph2":"Phase III","graph3":"Zenas BioPharma","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.20000000000000001,"dosageForm":"Infusion","sponsorNew":"Zenas BioPharma \/ SR One Capital Management","highestDevelopmentStatusID":"10","companyTruncated":"Zenas BioPharma \/ SR One Capital Management"},{"orgOrder":0,"company":"Zenas BioPharma","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Public Offering","leadProduct":"Obexelimab","moa":"Low affinity immunoglobulin gamma Fc region receptor II-b | B-lymphocyte antigen CD19","graph1":"Immunology","graph2":"Phase III","graph3":"Zenas BioPharma","amount2":0.26000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.26000000000000001,"dosageForm":"Infusion","sponsorNew":"Zenas BioPharma \/ Morgan Stanley","highestDevelopmentStatusID":"10","companyTruncated":"Zenas BioPharma \/ Morgan Stanley"},{"orgOrder":0,"company":"Zenas BioPharma","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Financing","leadProduct":"Obexelimab","moa":"Low affinity immunoglobulin gamma Fc region receptor II-b | B-lymphocyte antigen CD19","graph1":"Immunology","graph2":"Phase III","graph3":"Zenas BioPharma","amount2":0.29999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.29999999999999999,"dosageForm":"Injection","sponsorNew":"Zenas BioPharma \/ Royalty Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Zenas BioPharma \/ Royalty Pharma"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Felzartamab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Immunology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Felzartamab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Immunology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Felzartamab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Immunology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Mezagitamab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Immunology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Mezagitamab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Immunology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Mezagitamab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Immunology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"BioInvent","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2025","type":"Collaboration","leadProduct":"Mezagitamab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Immunology","graph2":"Phase III","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioInvent \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"BioInvent \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"BioInvent","sponsor":"XOMA","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2025","type":"Agreement","leadProduct":"Mezagitamab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Immunology","graph2":"Phase III","graph3":"BioInvent","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"BioInvent \/ XOMA","highestDevelopmentStatusID":"10","companyTruncated":"BioInvent \/ XOMA"},{"orgOrder":0,"company":"Omeros","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Narsoplimab","moa":"Mannan-binding lectin serine protease 2","graph1":"Immunology","graph2":"Phase III","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Omeros \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Omeros \/ Undisclosed"},{"orgOrder":0,"company":"Omeros","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Narsoplimab","moa":"Mannan-binding lectin serine protease 2","graph1":"Immunology","graph2":"Phase III","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Omeros \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Omeros \/ Undisclosed"},{"orgOrder":0,"company":"Omeros","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Narsoplimab","moa":"Mannan-binding lectin serine protease 2","graph1":"Immunology","graph2":"Phase III","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Omeros \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Omeros \/ Undisclosed"},{"orgOrder":0,"company":"Omeros","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Narsoplimab","moa":"Mannan-binding lectin serine protease 2","graph1":"Immunology","graph2":"Phase III","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Omeros \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Omeros \/ Undisclosed"},{"orgOrder":0,"company":"The Task Force for Global Health","sponsor":"United States Agency for International Development","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2016","type":"Inapplicable","leadProduct":"Doxycycline","moa":"Matrix metalloproteinase 13 | Bacterial 70S ribosome | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Matrix metalloproteinase 8","graph1":"Immunology","graph2":"Phase III","graph3":"The Task Force for Global Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"The Task Force for Global Health \/ United States Agency for International Development","highestDevelopmentStatusID":"10","companyTruncated":"The Task Force for Global Health \/ United States Agency for International Development"},{"orgOrder":0,"company":"The Task Force for Global Health","sponsor":"United States Agency for International Development","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2016","type":"Inapplicable","leadProduct":"Doxycycline","moa":"Matrix metalloproteinase 13 | Bacterial 70S ribosome | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Matrix metalloproteinase 8","graph1":"Immunology","graph2":"Phase III","graph3":"The Task Force for Global Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"The Task Force for Global Health \/ United States Agency for International Development","highestDevelopmentStatusID":"10","companyTruncated":"The Task Force for Global Health \/ United States Agency for International Development"},{"orgOrder":0,"company":"The Task Force for Global Health","sponsor":"United States Agency for International Development","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2016","type":"Inapplicable","leadProduct":"Doxycycline","moa":"Matrix metalloproteinase 13 | Bacterial 70S ribosome | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Matrix metalloproteinase 8","graph1":"Immunology","graph2":"Phase III","graph3":"The Task Force for Global Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"The Task Force for Global Health \/ United States Agency for International Development","highestDevelopmentStatusID":"10","companyTruncated":"The Task Force for Global Health \/ United States Agency for International Development"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dersimelagon","moa":"Melanocortin receptor 1","graph1":"Immunology","graph2":"Phase III","graph3":"Mitsubishi Tanabe Pharma America","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mitsubishi Tanabe Pharma America \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mitsubishi Tanabe Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dersimelagon","moa":"Melanocortin receptor 1","graph1":"Immunology","graph2":"Phase III","graph3":"Mitsubishi Tanabe Pharma America","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mitsubishi Tanabe Pharma America \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mitsubishi Tanabe Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Attune Health Research","sponsor":"Mallinckrodt Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2018","type":"Inapplicable","leadProduct":"Corticotropin","moa":"Melanocortin receptor 2","graph1":"Immunology","graph2":"Phase III","graph3":"Attune Health Research","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Attune Health Research \/ Mallinckrodt Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Attune Health Research \/ Mallinckrodt Pharmaceuticals"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"Cx601","moa":"Mesenchymal stem cells","graph1":"Immunology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2011","type":"Inapplicable","leadProduct":"Cx601","moa":"Mesenchymal stem cells","graph1":"Immunology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Ontamalimab","moa":"Mucosal addressin cell adhesion molecule-1","graph1":"Immunology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Ontamalimab","moa":"Mucosal addressin cell adhesion molecule-1","graph1":"Immunology","graph2":"Phase III","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Ontamalimab","moa":"Mucosal addressin cell adhesion molecule-1","graph1":"Immunology","graph2":"Phase III","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Ontamalimab","moa":"Mucosal addressin cell adhesion molecule-1","graph1":"Immunology","graph2":"Phase III","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Ontamalimab","moa":"Mucosal addressin cell adhesion molecule-1","graph1":"Immunology","graph2":"Phase III","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Ontamalimab","moa":"Mucosal addressin cell adhesion molecule-1","graph1":"Immunology","graph2":"Phase III","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Ontamalimab","moa":"Mucosal addressin cell adhesion molecule-1","graph1":"Immunology","graph2":"Phase III","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Ontamalimab","moa":"Mucosal addressin cell adhesion molecule-1","graph1":"Immunology","graph2":"Phase III","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"Magna Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Atropine","moa":"Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M2 | Muscarinic acetylcholine receptor M1","graph1":"Immunology","graph2":"Phase III","graph3":"Magna Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Magna Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Magna Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Magna Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Atropine","moa":"Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M2 | Muscarinic acetylcholine receptor M1","graph1":"Immunology","graph2":"Phase III","graph3":"Magna Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Magna Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Magna Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Unity Health Toronto","sponsor":"Li Ka Shing Knowledge Institute | University of Toronto","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Oseltamivir Phosphate","moa":"Neuraminidase","graph1":"Immunology","graph2":"Phase III","graph3":"Unity Health Toronto","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Unity Health Toronto \/ Li Ka Shing Knowledge Institute | University of Toronto","highestDevelopmentStatusID":"10","companyTruncated":"Unity Health Toronto \/ Li Ka Shing Knowledge Institute | University of Toronto"},{"orgOrder":0,"company":"NIHON PHARMACEUTICAL","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"NPB-01","moa":"NMDA receptor","graph1":"Immunology","graph2":"Phase III","graph3":"NIHON PHARMACEUTICAL","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NIHON PHARMACEUTICAL \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NIHON PHARMACEUTICAL \/ Undisclosed"},{"orgOrder":0,"company":"NIHON PHARMACEUTICAL","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"NPB-01","moa":"NMDA receptor","graph1":"Immunology","graph2":"Phase III","graph3":"NIHON PHARMACEUTICAL","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NIHON PHARMACEUTICAL \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NIHON PHARMACEUTICAL \/ Undisclosed"},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Pseudoephedrine","moa":"Norepinephrine transporter","graph1":"Immunology","graph2":"Phase III","graph3":"Hanmi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hanmi Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hanmi Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Statera Biopharma","sponsor":"EF Hutton","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Public Offering","leadProduct":"STAT-201","moa":"Opioid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Statera Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Statera Biopharma \/ EF Hutton","highestDevelopmentStatusID":"10","companyTruncated":"Statera Biopharma \/ EF Hutton"},{"orgOrder":0,"company":"Statera Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"STAT-201","moa":"Opioid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Statera Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Statera Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Statera Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"BAT1406","moa":"PCSK9","graph1":"Immunology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio-Thera Solutions \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Mesalazine","moa":"Peroxisome proliferator-activated receptor gamma | Cyclooxygenase | Arachidonate 5-lipoxygenase","graph1":"Immunology","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Ferring Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Mesalazine","moa":"Peroxisome proliferator-activated receptor gamma | Cyclooxygenase | Arachidonate 5-lipoxygenase","graph1":"Immunology","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Ferring Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Tillotts Pharma AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Mesalazine","moa":"Peroxisome proliferator-activated receptor gamma | Cyclooxygenase | Arachidonate 5-lipoxygenase","graph1":"Immunology","graph2":"Phase III","graph3":"Tillotts Pharma AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tillotts Pharma AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tillotts Pharma AG \/ Undisclosed"},{"orgOrder":0,"company":"Tillotts Pharma AG","sponsor":"Zeria Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Mesalazine","moa":"Peroxisome proliferator-activated receptor gamma | Cyclooxygenase | Arachidonate 5-lipoxygenase","graph1":"Immunology","graph2":"Phase III","graph3":"Tillotts Pharma AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tillotts Pharma AG \/ Zeria Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Tillotts Pharma AG \/ Zeria Pharmaceutical"},{"orgOrder":0,"company":"Tillotts Pharma AG","sponsor":"Zeria Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Mesalazine","moa":"Peroxisome proliferator-activated receptor gamma | Cyclooxygenase | Arachidonate 5-lipoxygenase","graph1":"Immunology","graph2":"Phase III","graph3":"Tillotts Pharma AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tillotts Pharma AG \/ Zeria Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Tillotts Pharma AG \/ Zeria Pharmaceutical"},{"orgOrder":0,"company":"EMET Pharmaceuticals, LLC","sponsor":"Eagle Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Mesalazine","moa":"Peroxisome proliferator-activated receptor gamma | Cyclooxygenase | Arachidonate 5-lipoxygenase","graph1":"Immunology","graph2":"Phase III","graph3":"EMET Pharmaceuticals, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EMET Pharmaceuticals, LLC \/ Eagle Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"EMET Pharmaceuticals, LLC \/ Eagle Pharmaceuticals"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Mesalazine","moa":"Peroxisome proliferator-activated receptor gamma | Cyclooxygenase | Arachidonate 5-lipoxygenase","graph1":"Immunology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Hospital Universitari Vall d'Hebron Research Institute","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"HPAPI","year":"2017","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Immunology","graph2":"Phase III","graph3":"Hospital Universitari Vall d'Hebron Research Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hospital Universitari Vall d'Hebron Research Institute \/ Celgene Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Hospital Universitari Vall d'Hebron Research Institute \/ Celgene Corporation"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"HPAPI","year":"2012","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Immunology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Immunology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"AR101","moa":"PKC-beta","graph1":"Immunology","graph2":"Phase III","graph3":"Aimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aimmune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aimmune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"AR101","moa":"PKC-beta","graph1":"Immunology","graph2":"Phase III","graph3":"Aimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aimmune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aimmune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"AR101","moa":"PKC-beta","graph1":"Immunology","graph2":"Phase III","graph3":"Aimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aimmune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aimmune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"AR101","moa":"PKC-beta","graph1":"Immunology","graph2":"Phase III","graph3":"Aimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aimmune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aimmune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"AR101","moa":"PKC-beta","graph1":"Immunology","graph2":"Phase III","graph3":"Aimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aimmune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aimmune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"AR101","moa":"PKC-beta","graph1":"Immunology","graph2":"Phase III","graph3":"Aimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aimmune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aimmune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"AR101","moa":"PKC-beta","graph1":"Immunology","graph2":"Phase III","graph3":"Aimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aimmune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aimmune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"AR101","moa":"PKC-beta","graph1":"Immunology","graph2":"Phase III","graph3":"Aimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Aimmune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aimmune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"AR101","moa":"PKC-beta","graph1":"Immunology","graph2":"Phase III","graph3":"Aimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aimmune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aimmune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"AR101","moa":"PKC-beta","graph1":"Immunology","graph2":"Phase III","graph3":"Aimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aimmune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aimmune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Lanadelumab","moa":"Plasma kallikrein","graph1":"Immunology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Lanadelumab","moa":"Plasma kallikrein","graph1":"Immunology","graph2":"Phase III","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SHIRE PLC \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"SHIRE PLC \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"C1 Esterase Inhibitor","moa":"Plasma protease C1 inhibitor","graph1":"Immunology","graph2":"Phase III","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"C1 Esterase Inhibitor","moa":"Plasma protease C1 inhibitor","graph1":"Immunology","graph2":"Phase III","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"C1 Esterase Inhibitor","moa":"Plasma protease C1 inhibitor","graph1":"Immunology","graph2":"Phase III","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSL Behring \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CSL Behring \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Nintedanib Esylate","moa":"Platelet-derived growth factor receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"CiVi Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Iloprost","moa":"Prostanoid IP receptor","graph1":"Immunology","graph2":"Phase III","graph3":"CiVi Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CiVi Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CiVi Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"EMS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BRAZIL","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Nimesulide","moa":"PTGS2","graph1":"Immunology","graph2":"Phase III","graph3":"EMS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"EMS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"EMS \/ Undisclosed"},{"orgOrder":0,"company":"R-Pharm","sponsor":"Exacte Labs | Ministry of Health, Russia | Scientific Center EFiS | Data Management 365","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"RUSSIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"RPH-104","moa":"receptor molecules","graph1":"Immunology","graph2":"Phase III","graph3":"R-Pharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"R-Pharm \/ Exacte Labs | Ministry of Health, Russia | Scientific Center EFiS | Data Management 365","highestDevelopmentStatusID":"10","companyTruncated":"R-Pharm \/ Exacte Labs | Ministry of Health, Russia | Scientific Center EFiS | Data Management 365"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Belumosudil","moa":"Rho-associated protein kinase 2","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Voclosporin","moa":"Serine\/threonine protein phosphatase 2B catalytic subunit, alpha isoform","graph1":"Immunology","graph2":"Phase III","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aurinia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aurinia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Aceneuramic Acid","moa":"Sialic acid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ultragenyx Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Aceneuramic Acid","moa":"Sialic acid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ultragenyx Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Aceneuramic Acid","moa":"Sialic acid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ultragenyx Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Inmunotek","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"MG01","moa":"Sigma-1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Inmunotek","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inmunotek \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Inmunotek \/ Undisclosed"},{"orgOrder":0,"company":"Inmunotek","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"MG01","moa":"Sigma-1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Inmunotek","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inmunotek \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Inmunotek \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Oligonucleotide","year":"2015","type":"Inapplicable","leadProduct":"GED-0301","moa":"SMAD-7 mRNA","graph1":"Immunology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Oligonucleotide","year":"2015","type":"Inapplicable","leadProduct":"GED-0301","moa":"SMAD-7 mRNA","graph1":"Immunology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Oligonucleotide","year":"2016","type":"Inapplicable","leadProduct":"GED-0301","moa":"SMAD-7 mRNA","graph1":"Immunology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Oligonucleotide","year":"2016","type":"Inapplicable","leadProduct":"GED-0301","moa":"SMAD-7 mRNA","graph1":"Immunology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Oligonucleotide","year":"2015","type":"Inapplicable","leadProduct":"GED-0301","moa":"SMAD-7 mRNA","graph1":"Immunology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Viatris","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2025","type":"Agreement","leadProduct":"Cenerimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase III","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Sosei Group Corporation \/ Viatris","highestDevelopmentStatusID":"10","companyTruncated":"Sosei Group Corporation \/ Viatris"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cenerimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase III","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Idorsia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Cenerimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase III","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Idorsia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Cenerimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase III","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Idorsia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Cenerimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase III","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Idorsia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Cenerimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase III","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Idorsia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Cenerimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase III","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Idorsia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cenerimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase III","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Idorsia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Viatris","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2025","type":"Collaboration","leadProduct":"Cenerimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase III","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Viatris","highestDevelopmentStatusID":"10","companyTruncated":"Idorsia Pharmaceuticals \/ Viatris"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Acquisition","leadProduct":"Etrasimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":6.7000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":6.7000000000000002,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Pfizer Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Acquisition","leadProduct":"Etrasimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":6.7000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":6.7000000000000002,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Pfizer Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Etrasimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Etrasimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Pfizer Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Etrasimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Etrasimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Pfizer Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Etrasimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Pfizer Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Etrasimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Pfizer Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Etrasimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Pfizer Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Etrasimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Etrasimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Pfizer Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Etrasimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Etrasimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Everstar Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Etrasimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase III","graph3":"Everstar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Everstar Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Everstar Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ozanimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Ozanimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Ozanimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Ozanimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Ozanimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ozanimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ozanimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Amino Acid","year":"2022","type":"Inapplicable","leadProduct":"Etrasimod Arginine","moa":"Sphingosine 1-phosphate receptor Edg-8 | Sphingosine 1-phosphate receptor Edg-6 | Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Amino Acid","year":"2021","type":"Inapplicable","leadProduct":"Etrasimod Arginine","moa":"Sphingosine 1-phosphate receptor Edg-8 | Sphingosine 1-phosphate receptor Edg-6 | Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Butenafine Hydrochloride","moa":"Squalene monooxygenase","graph1":"Immunology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Butenafine Hydrochloride","moa":"Squalene monooxygenase","graph1":"Immunology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Dressing","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bio Farma","sponsor":"RS Umum Pusat Sanglah","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDONESIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Hepatitis B Vaccine","moa":"Surface antigen (HBsAg)","graph1":"Immunology","graph2":"Phase III","graph3":"Bio Farma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio Farma \/ RS Umum Pusat Sanglah","highestDevelopmentStatusID":"10","companyTruncated":"Bio Farma \/ RS Umum Pusat Sanglah"},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"R788","moa":"Syk","graph1":"Immunology","graph2":"Phase III","graph3":"Kissei Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kissei Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kissei Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Equillium","sponsor":"Biocon","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Itolizumab","moa":"T-cell differentiation antigen CD6","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Equillium \/ Biocon","highestDevelopmentStatusID":"10","companyTruncated":"Equillium \/ Biocon"},{"orgOrder":0,"company":"Equillium","sponsor":"Biocon","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Itolizumab","moa":"T-cell differentiation antigen CD6","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Equillium \/ Biocon","highestDevelopmentStatusID":"10","companyTruncated":"Equillium \/ Biocon"},{"orgOrder":0,"company":"Equillium","sponsor":"Biocon","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Itolizumab","moa":"T-cell differentiation antigen CD6","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Equillium \/ Biocon","highestDevelopmentStatusID":"10","companyTruncated":"Equillium \/ Biocon"},{"orgOrder":0,"company":"Equillium","sponsor":"Biocon","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Itolizumab","moa":"T-cell differentiation antigen CD6","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Equillium \/ Biocon","highestDevelopmentStatusID":"10","companyTruncated":"Equillium \/ Biocon"},{"orgOrder":0,"company":"Equillium","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Itolizumab","moa":"T-cell differentiation antigen CD6","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Equillium \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Equillium \/ Undisclosed"},{"orgOrder":0,"company":"Equillium","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Agreement","leadProduct":"Itolizumab","moa":"T-cell differentiation antigen CD6","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0.16,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.16,"dosageForm":"Infusion","sponsorNew":"Equillium \/ Ono Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Equillium \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Equillium","sponsor":"Biocon","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Itolizumab","moa":"T-cell differentiation antigen CD6","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Equillium \/ Biocon","highestDevelopmentStatusID":"10","companyTruncated":"Equillium \/ Biocon"},{"orgOrder":0,"company":"Equillium","sponsor":"Biocon","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Itolizumab","moa":"T-cell differentiation antigen CD6","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Equillium \/ Biocon","highestDevelopmentStatusID":"10","companyTruncated":"Equillium \/ Biocon"},{"orgOrder":0,"company":"Equillium","sponsor":"Decheng Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Public Offering","leadProduct":"Itolizumab","moa":"T-cell differentiation antigen CD6","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.029999999999999999,"dosageForm":"Infusion","sponsorNew":"Equillium \/ Decheng Capital","highestDevelopmentStatusID":"10","companyTruncated":"Equillium \/ Decheng Capital"},{"orgOrder":0,"company":"Equillium","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Itolizumab","moa":"T-cell differentiation antigen CD6","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Equillium \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Equillium \/ Undisclosed"},{"orgOrder":0,"company":"Equillium","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Itolizumab","moa":"T-cell differentiation antigen CD6","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Equillium \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Equillium \/ Undisclosed"},{"orgOrder":0,"company":"Equillium","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Itolizumab","moa":"T-cell differentiation antigen CD6","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Equillium \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Equillium \/ Undisclosed"},{"orgOrder":0,"company":"Equillium","sponsor":"Biocon","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Itolizumab","moa":"T-cell differentiation antigen CD6","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Equillium \/ Biocon","highestDevelopmentStatusID":"10","companyTruncated":"Equillium \/ Biocon"},{"orgOrder":0,"company":"Equillium","sponsor":"Biocon","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Itolizumab","moa":"T-cell differentiation antigen CD6","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Equillium \/ Biocon","highestDevelopmentStatusID":"10","companyTruncated":"Equillium \/ Biocon"},{"orgOrder":0,"company":"Equillium","sponsor":"Biocon","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Itolizumab","moa":"T-cell differentiation antigen CD6","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Equillium \/ Biocon","highestDevelopmentStatusID":"10","companyTruncated":"Equillium \/ Biocon"},{"orgOrder":0,"company":"Equillium","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Itolizumab","moa":"T-cell differentiation antigen CD6","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Equillium \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Equillium \/ Undisclosed"},{"orgOrder":0,"company":"Equillium","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Termination","leadProduct":"Itolizumab","moa":"T-cell differentiation antigen CD6","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Equillium \/ Ono Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Equillium \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Equillium","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Itolizumab","moa":"T-cell differentiation antigen CD6","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Equillium \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Equillium \/ Undisclosed"},{"orgOrder":0,"company":"University of Oxford","sponsor":"Oxford University Hospitals NHS Trust | Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Antithymocyte Globulin","moa":"T-cell surface glycoprotein CD1a (CD1A)","graph1":"Immunology","graph2":"Phase III","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Oxford \/ Oxford University Hospitals NHS Trust | Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"University of Oxford \/ Oxford University Hospitals NHS Trust | Sanofi"},{"orgOrder":0,"company":"Neovii","sponsor":"Eurotrials Brasil | Recerca Cl\u00ednica | PsyConsult","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Atg-Fresenius S","moa":"T-cells (T-cells)","graph1":"Immunology","graph2":"Phase III","graph3":"Neovii","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neovii \/ Eurotrials Brasil | Recerca Cl\u00ednica | PsyConsult","highestDevelopmentStatusID":"10","companyTruncated":"Neovii \/ Eurotrials Brasil | Recerca Cl\u00ednica | PsyConsult"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Medsenic","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2022","type":"Acquisition","leadProduct":"Arsenic Trioxide","moa":"Thioredoxin reductase 1","graph1":"Immunology","graph2":"Phase III","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bone Therapeutics \/ Medsenic","highestDevelopmentStatusID":"10","companyTruncated":"Bone Therapeutics \/ Medsenic"},{"orgOrder":0,"company":"Medsenic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Arsenic Trioxide","moa":"Thioredoxin reductase 1","graph1":"Immunology","graph2":"Phase III","graph3":"Medsenic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medsenic \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Medsenic \/ Undisclosed"},{"orgOrder":0,"company":"Medsenic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Arsenic Trioxide","moa":"||Thioredoxin reductase 1","graph1":"Immunology","graph2":"Phase III","graph3":"Medsenic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medsenic \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Medsenic \/ Undisclosed"},{"orgOrder":0,"company":"Medsenic","sponsor":"Phebra","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Partnership","leadProduct":"Arsenic Trioxide","moa":"Thioredoxin reductase 1","graph1":"Immunology","graph2":"Phase III","graph3":"Medsenic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medsenic \/ Phebra","highestDevelopmentStatusID":"10","companyTruncated":"Medsenic \/ Phebra"},{"orgOrder":0,"company":"Medsenic","sponsor":"Phebra","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"Arsenic Trioxide","moa":"Thioredoxin reductase 1","graph1":"Immunology","graph2":"Phase III","graph3":"Medsenic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medsenic \/ Phebra","highestDevelopmentStatusID":"10","companyTruncated":"Medsenic \/ Phebra"},{"orgOrder":0,"company":"Eisai Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Avatrombopag Maleate","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Eisai Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eisai Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eisai Inc \/ Undisclosed"},{"orgOrder":0,"company":"National Institute of Blood and Marrow Transplant, Pakistan","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"PAKISTAN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Eltrombopag","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Phase III","graph3":"National Institute of Blood and Marrow Transplant, Pakistan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institute of Blood and Marrow Transplant, Pakistan \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"National Institute of Blood and Marrow Transplant, Pakistan \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Eltrombopag","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Eltrombopag","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Eltrombopag","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Eltrombopag","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"McMaster University","sponsor":"GSK | Hamilton Health Sciences | Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Eltrombopag","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Phase III","graph3":"McMaster University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Pill","sponsorNew":"McMaster University \/ GSK | Hamilton Health Sciences | Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"McMaster University \/ GSK | Hamilton Health Sciences | Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Hetrombopag","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Hetrombopag Olamine","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Hetrombopag Olamine","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Hetrombopag Olamine","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Hetrombopag Olamine","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Semaxanib","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kyowa Kirin \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kyowa Kirin \/ Undisclosed"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Semaxanib","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kyowa Kirin \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kyowa Kirin \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Semaxanib","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Semaxanib","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Semaxanib","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Semaxanib","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase III","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase III","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"University Medical Center Groningen","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase III","graph3":"University Medical Center Groningen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Medical Center Groningen \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"University Medical Center Groningen \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Arthritis & Rheumatic Disease Specialties Research","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase III","graph3":"Arthritis & Rheumatic Disease Specialties Research","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arthritis & Rheumatic Disease Specialties Research \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Arthritis & Rheumatic Disease Specialties Research \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Ono Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Belatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Belatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Belatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Continent Pharmaceutical","sponsor":"Shanghai Genomics, Inc. | GNI Group","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"TNF","graph1":"Immunology","graph2":"Phase III","graph3":"Beijing Continent Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Continent Pharmaceutical \/ Shanghai Genomics, Inc. | GNI Group","highestDevelopmentStatusID":"10","companyTruncated":"Beijing Continent Pharmaceutical \/ Shanghai Genomics, Inc. | GNI Group"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"BAT2506","moa":"TNF alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio-Thera Solutions \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"The First Hospital of Jilin University","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"BAT2506","moa":"TNF alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio-Thera Solutions \/ The First Hospital of Jilin University","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera Solutions \/ The First Hospital of Jilin University"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"Korea Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody-drug Conjugate","year":"2010","type":"Inapplicable","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Korea Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Korea Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Korea Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2011","type":"Inapplicable","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ UCB Pharma S.A","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ UCB Pharma S.A"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody-drug Conjugate","year":"2010","type":"Inapplicable","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"PRA Health Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody-drug Conjugate","year":"2012","type":"Inapplicable","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ PRA Health Sciences","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ PRA Health Sciences"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody-drug Conjugate","year":"2015","type":"Inapplicable","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody-drug Conjugate","year":"2010","type":"Inapplicable","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody-drug Conjugate","year":"2018","type":"Inapplicable","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"Gastroenterology Research of America","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2013","type":"Inapplicable","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Gastroenterology Research of America","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gastroenterology Research of America \/ UCB Pharma S.A","highestDevelopmentStatusID":"10","companyTruncated":"Gastroenterology Research of America \/ UCB Pharma S.A"},{"orgOrder":0,"company":"Oklahoma Medical Research Foundation","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2010","type":"Inapplicable","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Oklahoma Medical Research Foundation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oklahoma Medical Research Foundation \/ UCB Pharma S.A","highestDevelopmentStatusID":"10","companyTruncated":"Oklahoma Medical Research Foundation \/ UCB Pharma S.A"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"ABP 710","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"BI695501","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"BI695501","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"BI695501","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"BI695501","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Epirus Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"BOW015","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Epirus Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Epirus Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Epirus Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"CDP870","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Astellas Pharma \/ UCB Pharma S.A","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ UCB Pharma S.A"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"CHS-0214","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Coherus Biosciences \/ Daiichi Sankyo","highestDevelopmentStatusID":"10","companyTruncated":"Coherus Biosciences \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Daiichi Sankyo | SHIRE PLC","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"CHS-0214","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Coherus Biosciences \/ Daiichi Sankyo | SHIRE PLC","highestDevelopmentStatusID":"10","companyTruncated":"Coherus Biosciences \/ Daiichi Sankyo | SHIRE PLC"},{"orgOrder":0,"company":"Shanghai Biomabs Pharmaceutical Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"CMAB008","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Shanghai Biomabs Pharmaceutical Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Biomabs Pharmaceutical Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Biomabs Pharmaceutical Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"CT-P13","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celltrion \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Celltrion \/ Pfizer Inc"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"CT-P13","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"CT-P13","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"CT-P13","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Hanwha Chemical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Hanwha Chemical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hanwha Chemical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hanwha Chemical \/ Undisclosed"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Samsung Bioepis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Samsung Bioepis \/ Undisclosed"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Samsung Bioepis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Samsung Bioepis \/ Undisclosed"},{"orgOrder":0,"company":"Sunshine Guojian Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Sunshine Guojian Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Sunshine Guojian Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sunshine Guojian Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"LG Life Sciences","sponsor":"Mochida Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"LG Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LG Life Sciences \/ Mochida Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"LG Life Sciences \/ Mochida Pharmaceutical"},{"orgOrder":0,"company":"LG Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"LG Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LG Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"LG Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Giannina Gaslini Institute","sponsor":"Agenzia Italiana del Farmaco | Compagnia di San Paolo | Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ITALY","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Giannina Gaslini Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Giannina Gaslini Institute \/ Agenzia Italiana del Farmaco | Compagnia di San Paolo | Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Giannina Gaslini Institute \/ Agenzia Italiana del Farmaco | Compagnia di San Paolo | Pfizer Inc"},{"orgOrder":0,"company":"FARMAK, a.s","sponsor":"Sunshine Guojian Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CZECH REPUBLIC","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"FARMAK, a.s","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"FARMAK, a.s \/ Sunshine Guojian Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"FARMAK, a.s \/ Sunshine Guojian Pharmaceutical"},{"orgOrder":0,"company":"Mabxience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Mabxience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mabxience \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mabxience \/ Undisclosed"},{"orgOrder":0,"company":"Mabxience","sponsor":"Intas Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SPAIN","productType":"Protein","year":"2023","type":"Licensing Agreement","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Mabxience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mabxience \/ Intas Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Mabxience \/ Intas Pharmaceuticals"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Viatris","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Viatris \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Viatris \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"EMS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BRAZIL","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"EMS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EMS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"EMS \/ Undisclosed"},{"orgOrder":0,"company":"Gema Biotech","sponsor":"QUID Quality in Drugs and Devices LA Consulting","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Gema Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gema Biotech \/ QUID Quality in Drugs and Devices LA Consulting","highestDevelopmentStatusID":"10","companyTruncated":"Gema Biotech \/ QUID Quality in Drugs and Devices LA Consulting"},{"orgOrder":0,"company":"Gema Biotech","sponsor":"QUID Quality in Drugs and Devices LA Consulting","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Gema Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gema Biotech \/ QUID Quality in Drugs and Devices LA Consulting","highestDevelopmentStatusID":"10","companyTruncated":"Gema Biotech \/ QUID Quality in Drugs and Devices LA Consulting"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"FKB327","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kyowa Kirin \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kyowa Kirin \/ Undisclosed"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"FKB327","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kyowa Kirin \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kyowa Kirin \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Agreement","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio-Thera Solutions \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera Solutions \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Accord BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Licensing Agreement","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0.16,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.16,"dosageForm":"Injection","sponsorNew":"Bio-Thera Solutions \/ Accord BioPharma","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera Solutions \/ Accord BioPharma"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio-Thera Solutions \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"STADA Arzneimittel","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Licensing Agreement","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0.16,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.16,"dosageForm":"Injection","sponsorNew":"Bio-Thera Solutions \/ STADA Arzneimittel","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera Solutions \/ STADA Arzneimittel"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio-Thera Solutions \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio-Thera Solutions \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera Solutions \/ Undisclosed"},{"orgOrder":0,"company":"University Ghent","sponsor":"Merck & Co | the Flanders Institute for Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"University Ghent","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Ghent \/ Merck & Co | the Flanders Institute for Biotechnology","highestDevelopmentStatusID":"10","companyTruncated":"University Ghent \/ Merck & Co | the Flanders Institute for Biotechnology"},{"orgOrder":0,"company":"IMM Jo\u00e3o Lobo Antunes","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"PORTUGAL","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"IMM Jo\u00e3o Lobo Antunes","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"IMM Jo\u00e3o Lobo Antunes \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"IMM Jo\u00e3o Lobo Antunes \/ Merck & Co"},{"orgOrder":0,"company":"The Leeds Teaching Hospitals NHS Trust","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"The Leeds Teaching Hospitals NHS Trust","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Leeds Teaching Hospitals NHS Trust \/ Janssen Pharmaceutica","highestDevelopmentStatusID":"10","companyTruncated":"The Leeds Teaching Hospitals NHS Trust \/ Janssen Pharmaceutica"},{"orgOrder":0,"company":"JANSSEN BIOTECH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"JANSSEN BIOTECH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"JANSSEN BIOTECH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"JANSSEN BIOTECH \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Centocor","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Centocor","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Centocor \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Centocor \/ Merck & Co"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Centocor","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Centocor","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Centocor \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Centocor \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Centocor","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Centocor","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Centocor \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Centocor \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"GP2015","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sandoz B2B \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sandoz B2B \/ Undisclosed"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Samsung Bioepis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Samsung Bioepis \/ Undisclosed"},{"orgOrder":0,"company":"Academisch Medisch Centrum - Universiteit van Amsterdam","sponsor":"Celltrion","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Academisch Medisch Centrum - Universiteit van Amsterdam","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Academisch Medisch Centrum - Universiteit van Amsterdam \/ Celltrion","highestDevelopmentStatusID":"10","companyTruncated":"Academisch Medisch Centrum - Universiteit van Amsterdam \/ Celltrion"},{"orgOrder":0,"company":"JANSSEN BIOTECH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"JANSSEN BIOTECH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"JANSSEN BIOTECH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"JANSSEN BIOTECH \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"PRA Health Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"MSB11022","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Fresenius Kabi AG \/ PRA Health Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Fresenius Kabi AG \/ PRA Health Sciences"},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"MSB11022","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fresenius Kabi AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Fresenius Kabi AG \/ Undisclosed"},{"orgOrder":0,"company":"Nichi-Iko Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"NI-071","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Nichi-Iko Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nichi-Iko Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nichi-Iko Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Nichi-Iko Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"NI-071","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Nichi-Iko Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nichi-Iko Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nichi-Iko Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"PF-06410293","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"PF-06410293","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"PF-06438179","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"TA-650","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mitsubishi Tanabe Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mitsubishi Tanabe Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"TA-650","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mitsubishi Tanabe Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mitsubishi Tanabe Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Enzene Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Enzene Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enzene Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Enzene Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"LG Life Sciences","sponsor":"Mochida Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"LG Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LG Life Sciences \/ Mochida Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"LG Life Sciences \/ Mochida Pharmaceutical"},{"orgOrder":0,"company":"Odense University Hospital","sponsor":"University of Southern Denmark | Hvidovre University Hospital | Aarhus University Hospital | AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Odense University Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Odense University Hospital \/ University of Southern Denmark | Hvidovre University Hospital | Aarhus University Hospital | AbbVie Inc","highestDevelopmentStatusID":"10","companyTruncated":"Odense University Hospital \/ University of Southern Denmark | Hvidovre University Hospital | Aarhus University Hospital | AbbVie Inc"},{"orgOrder":0,"company":"Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa","sponsor":"Abbott Laboratories | TFS Trial Form Support","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa \/ Abbott Laboratories | TFS Trial Form Support","highestDevelopmentStatusID":"10","companyTruncated":"Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa \/ Abbott Laboratories | TFS Trial Form Support"},{"orgOrder":0,"company":"Heinrich-Heine University, Duesseldorf","sponsor":"Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Heinrich-Heine University, Duesseldorf","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Heinrich-Heine University, Duesseldorf \/ Abbott Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Heinrich-Heine University, Duesseldorf \/ Abbott Laboratories"},{"orgOrder":0,"company":"Alvotech","sponsor":"DKSH","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2020","type":"Partnership","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alvotech \/ DKSH","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/ DKSH"},{"orgOrder":0,"company":"Tel Aviv Sourasky Medical Center (Ichilov Hospital)","sponsor":"Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Tel Aviv Sourasky Medical Center (Ichilov Hospital)","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tel Aviv Sourasky Medical Center (Ichilov Hospital) \/ Abbott Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Tel Aviv Sourasky Medical Center (Ichilov Hospital) \/ Abbott Laboratories"},{"orgOrder":0,"company":"Clalit","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Clalit","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clalit \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Clalit \/ Undisclosed"},{"orgOrder":0,"company":"CinnaGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRAN","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"CinnaGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CinnaGen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CinnaGen \/ Undisclosed"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Abbott Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abbott Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Abbott Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abbott Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ GSK"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Tulisokibart","moa":"TNFSF15","graph1":"Immunology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Tulisokibart","moa":"TNFSF15","graph1":"Immunology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Thermo Fisher Scientific","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Tulisokibart","moa":"TNFSF15","graph1":"Immunology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Thermo Fisher Scientific","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Thermo Fisher Scientific"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Tulisokibart","moa":"TNFSF15","graph1":"Immunology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Tulisokibart","moa":"TNFSF15","graph1":"Immunology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"Toll-like receptor 9","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"InDex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"Toll-like receptor 9","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"InDex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"Toll-like receptor 9","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"InDex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"Toll-like receptor 9","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"InDex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"Toll-like receptor 9","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"InDex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"Toll-like receptor 9","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"InDex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"Toll-like receptor 9","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"InDex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"Toll-like receptor 9","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"InDex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"Toll-like receptor 9","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"InDex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"Toll-like receptor 9","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"InDex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"Toll-like receptor 9","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"InDex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Viatris","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2023","type":"Licensing Agreement","leadProduct":"Cobitolimod","moa":"Toll-like receptor 9","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.050000000000000003,"dosageForm":"Suppository","sponsorNew":"InDex Pharmaceuticals \/ Viatris","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Viatris"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"Toll-like receptor 9","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"InDex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"Toll-like receptor 9","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"InDex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"Toll-like receptor 9","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"InDex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"Toll-like receptor 9","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"InDex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"Toll-like receptor 9","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"InDex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Vinnova","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2020","type":"Funding","leadProduct":"Cobitolimod","moa":"Toll-like receptor 9","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"InDex Pharmaceuticals \/ Vinnova","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Vinnova"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2011","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"Toll-like receptor 9","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InDex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"Toll-like receptor 9","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InDex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2017","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"Toll-like receptor 9","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InDex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"Toll-like receptor 9","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InDex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Immunology","graph2":"Phase III","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NYU Langone Health \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"NYU Langone Health \/ National Institutes of Health"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Herombopag","moa":"TPO receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Montreal Heart Institute","sponsor":"COVID-19 Therapeutics Accelerator","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2020","type":"Funding","leadProduct":"Colchicine","moa":"Tubulin","graph1":"Immunology","graph2":"Phase III","graph3":"Montreal Heart Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Montreal Heart Institute \/ COVID-19 Therapeutics Accelerator","highestDevelopmentStatusID":"10","companyTruncated":"Montreal Heart Institute \/ COVID-19 Therapeutics Accelerator"},{"orgOrder":0,"company":"Leiden University Medical Center","sponsor":"Dutch Kidney Foundation | GSK","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Belimumab","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase III","graph3":"Leiden University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leiden University Medical Center \/ Dutch Kidney Foundation | GSK","highestDevelopmentStatusID":"10","companyTruncated":"Leiden University Medical Center \/ Dutch Kidney Foundation | GSK"},{"orgOrder":0,"company":"Anthera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Blisibimod","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase III","graph3":"Anthera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Anthera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Anthera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Anthera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Blisibimod","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase III","graph3":"Anthera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Anthera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Anthera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Anthera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Blisibimod","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase III","graph3":"Anthera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Anthera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Anthera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"LY2127399","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"LY2127399","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"LY2127399","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"LY2127399","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"LY2127399","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"LY2127399","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"LY2127399","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"LY2127399","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"LY2127399","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Tabalumab","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Tabalumab","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Tabalumab","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Ianalumab","moa":"Tumor necrosis factor receptor superfamily member 13C","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Ianalumab","moa":"Tumor necrosis factor receptor superfamily member 13C","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Ianalumab","moa":"Tumor necrosis factor receptor superfamily member 13C","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Ianalumab","moa":"Tumor necrosis factor receptor superfamily member 13C","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Ianalumab","moa":"Tumor necrosis factor receptor superfamily member 13C","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Ianalumab","moa":"Tumor necrosis factor receptor superfamily member 13C","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Ianalumab","moa":"Tumor necrosis factor receptor superfamily member 13C","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Ianalumab","moa":"Tumor necrosis factor receptor superfamily member 13C","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Ianalumab","moa":"Tumor necrosis factor receptor superfamily member 13C","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Ianalumab","moa":"Tumor necrosis factor receptor superfamily member 13C","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"VAY736","moa":"Tumor necrosis factor receptor superfamily member 13C","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"VAY736","moa":"Tumor necrosis factor receptor superfamily member 13C","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"VAY736","moa":"Tumor necrosis factor receptor superfamily member 13C","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"VAY736","moa":"Tumor necrosis factor receptor superfamily member 13C","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"VAY736","moa":"Tumor necrosis factor receptor superfamily member 13C","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"VAY736","moa":"Tumor necrosis factor receptor superfamily member 13C","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"HONG KONG","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Andrographolide","moa":"Inflammation pathogenesis (IP)||Tumor necrosis factor; Interleukin-1 beta; Interleukin-6; Nuclear factor NF-kappa-B p100 subunit; Nuclear factor NF-kappa-B p105 subunit","graph1":"Immunology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Nutrition Science Partners","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"HONG KONG","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Andrographolide","moa":"Inflammation pathogenesis (IP)||Tumor necrosis factor; Interleukin-1 beta; Interleukin-6; Nuclear factor NF-kappa-B p100 subunit; Nuclear factor NF-kappa-B p105 subunit","graph1":"Immunology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Nutrition Science Partners","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Nutrition Science Partners"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Zasocitinib","moa":"TYK2","graph1":"Immunology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Zasocitinib","moa":"TYK2","graph1":"Immunology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Hangzhou Highlightll Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"TLL-018","moa":"TYK2\/JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Hangzhou Highlightll Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hangzhou Highlightll Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hangzhou Highlightll Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Hangzhou Highlightll Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"TLL-018","moa":"TYK2\/JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Hangzhou Highlightll Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hangzhou Highlightll Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hangzhou Highlightll Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Hangzhou Highlightll Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"TLL-018","moa":"TYK2\/JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Hangzhou Highlightll Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hangzhou Highlightll Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hangzhou Highlightll Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Hangzhou Highlightll Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"TLL-018","moa":"TYK2\/JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Hangzhou Highlightll Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hangzhou Highlightll Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hangzhou Highlightll Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"CAS 1310726-60-3","moa":"tyrosine kinase inhibitors: janus kinase inhibitors","graph1":"Immunology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ONO-4059","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase III","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ono Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ono Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Orelabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase III","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Orelabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase III","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Orelabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase III","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Orelabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase III","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Rilzabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Rilzabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Massachusetts General Hospital","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Massachusetts General Hospital"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Rilzabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Rilzabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Rilzabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Rilzabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Rilzabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Itacitinib","moa":"Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Itacitinib","moa":"Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Itacitinib","moa":"Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Itacitinib","moa":"Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Itacitinib","moa":"||Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Roivant Sciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Brepocitinib","moa":"Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase TYK2","graph1":"Immunology","graph2":"Phase III","graph3":"Roivant Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Roivant Sciences \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Roivant Sciences \/ Pfizer Inc"},{"orgOrder":0,"company":"Priovant Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Brepocitinib","moa":"Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase TYK2","graph1":"Immunology","graph2":"Phase III","graph3":"Priovant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Priovant Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Priovant Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Priovant Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Brepocitinib","moa":"Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase TYK2","graph1":"Immunology","graph2":"Phase III","graph3":"Priovant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Priovant Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Priovant Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"University Hospital, Bordeaux","sponsor":"Eli Lilly | Biogen | Ministry for Health and Solidarity, France","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"University Hospital, Bordeaux","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital, Bordeaux \/ Eli Lilly | Biogen | Ministry for Health and Solidarity, France","highestDevelopmentStatusID":"10","companyTruncated":"University Hospital, Bordeaux \/ Eli Lilly | Biogen | Ministry for Health and Solidarity, France"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"McMaster University","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Phase III","graph3":"McMaster University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"McMaster University \/ AbbVie Inc","highestDevelopmentStatusID":"10","companyTruncated":"McMaster University \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Lupus Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Partnership","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Phase III","graph3":"Lupus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Lupus Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"10","companyTruncated":"Lupus Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Fostamatinib","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Fostamatinib","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Fostamatinib","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Fostamatinib","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Fostamatinib","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Fostamatinib","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Fostamatinib","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Fostamatinib","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Fostamatinib","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Fostamatinib","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Fostamatinib","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Fostamatinib","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Fostamatinib","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Fostamatinib","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Phase III","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rigel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Rigel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Phase III","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rigel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Rigel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Phase III","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rigel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Rigel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Phase III","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rigel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Rigel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"HONG KONG","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Sovleplenib","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"HONG KONG","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sovleplenib","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"HONG KONG","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Sovleplenib","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"HONG KONG","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Sovleplenib","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"HONG KONG","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Sovleplenib","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"HONG KONG","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Sovleplenib","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"HONG KONG","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Sovleplenib","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"HONG KONG","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sovleplenib","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"HONG KONG","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sovleplenib","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Immunology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Immunology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Galapagos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galapagos \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Galapagos \/ Undisclosed"},{"orgOrder":0,"company":"Galapagos","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galapagos \/ Gilead Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Galapagos \/ Gilead Sciences"},{"orgOrder":0,"company":"Galapagos","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galapagos \/ Gilead Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Galapagos \/ Gilead Sciences"},{"orgOrder":0,"company":"Alfasigma","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ITALY","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Alfasigma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alfasigma \/ Gilead Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Alfasigma \/ Gilead Sciences"},{"orgOrder":0,"company":"Alfasigma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ITALY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Alfasigma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alfasigma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alfasigma \/ Undisclosed"},{"orgOrder":0,"company":"Galapagos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galapagos \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Galapagos \/ Undisclosed"},{"orgOrder":0,"company":"Galapagos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galapagos \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Galapagos \/ Undisclosed"},{"orgOrder":0,"company":"Alfasigma","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ITALY","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Alfasigma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Alfasigma \/ Gilead Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Alfasigma \/ Gilead Sciences"},{"orgOrder":0,"company":"Alfasigma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ITALY","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Alfasigma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Alfasigma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alfasigma \/ Undisclosed"},{"orgOrder":0,"company":"Galapagos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Galapagos \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Galapagos \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Galapagos","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Galapagos","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Galapagos"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Galapagos","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Galapagos","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Galapagos"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Galapagos","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Galapagos","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Galapagos"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Galapagos","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Galapagos","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Galapagos"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Amino Acid","year":"2020","type":"Collaboration","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Ampio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ampio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ampio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2010","type":"Inapplicable","leadProduct":"Adult Human Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Undisclosed"},{"orgOrder":0,"company":"Abdi Ibrahim","sponsor":"Istanbul Umraniye Training and Research Hospital | Diskapi Yildirim Beyazit Education and Research Hospital | Antalya Training and Research Hospital | Dokuz Eylul University | Ankara City Hospital Bilkent | Kahramanmaras Sutcu Imam University | Uludag Uni","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TURKEY","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"AI201901","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Abdi Ibrahim","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abdi Ibrahim \/ Istanbul Umraniye Training and Research Hospital | Diskapi Yildirim Beyazit Education and Research Hospital | Antalya Training and Research Hospital | Dokuz Eylul University | Ankara City Hospital Bilkent | Kahramanmaras Sutcu Imam University | Uludag Uni","highestDevelopmentStatusID":"10","companyTruncated":"Abdi Ibrahim \/ Istanbul Umraniye Training and Research Hospital | Diskapi Yildirim Beyazit Education and Research Hospital | Antalya Training and Research Hospital | Dokuz Eylul University | Ankara City Hospital Bilkent | Kahramanmaras Sutcu Imam University | Uludag Uni"},{"orgOrder":0,"company":"Alloksys Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Alkaline Phosphatase","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Alloksys Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alloksys Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alloksys Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Biocad","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"RUSSIA","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"BCD-055","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Biocad","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocad \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biocad \/ Undisclosed"},{"orgOrder":0,"company":"Biocad","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"RUSSIA","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"BCD-055","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Biocad","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocad \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biocad \/ Undisclosed"},{"orgOrder":0,"company":"ALK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Birch Pollen Extract","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ALK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ALK \/ Undisclosed"},{"orgOrder":0,"company":"ALK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Birch Pollen Extract","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ALK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ALK \/ Undisclosed"},{"orgOrder":0,"company":"Stallergenes Greer","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Birch Pollen Extract","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Stallergenes Greer","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stallergenes Greer \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Stallergenes Greer \/ Undisclosed"},{"orgOrder":0,"company":"Chang Gung Memorial Hospital","sponsor":"Committee on Chinese Medicine and Pharmacy","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Bu Zhong Yi Qi Tang","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Chang Gung Memorial Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Chang Gung Memorial Hospital \/ Committee on Chinese Medicine and Pharmacy","highestDevelopmentStatusID":"10","companyTruncated":"Chang Gung Memorial Hospital \/ Committee on Chinese Medicine and Pharmacy"},{"orgOrder":0,"company":"Radboud University Medical Center","sponsor":"UMC Utrecht | Prothya Biosolutions","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"C1-esterase Inhibitor","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Radboud University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radboud University Medical Center \/ UMC Utrecht | Prothya Biosolutions","highestDevelopmentStatusID":"10","companyTruncated":"Radboud University Medical Center \/ UMC Utrecht | Prothya Biosolutions"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"D9421-C","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"DBV712","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"DBV Technologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"DBV Technologies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"DBV Technologies \/ Undisclosed"},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"DBV712","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"DBV Technologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DBV Technologies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"DBV Technologies \/ Undisclosed"},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"DBV712","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"DBV Technologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DBV Technologies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"DBV Technologies \/ Undisclosed"},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"DBV712","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"DBV Technologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DBV Technologies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"DBV Technologies \/ Undisclosed"},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"DBV712","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"DBV Technologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DBV Technologies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"DBV Technologies \/ Undisclosed"},{"orgOrder":0,"company":"University of S\u00e3o Paulo General Hospital","sponsor":"Butantan Institute","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BRAZIL","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Dengue 1,2,3,4 (attenuated) Vaccine","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"University of S\u00e3o Paulo General Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of S\u00e3o Paulo General Hospital \/ Butantan Institute","highestDevelopmentStatusID":"10","companyTruncated":"University of S\u00e3o Paulo General Hospital \/ Butantan Institute"},{"orgOrder":0,"company":"EMS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BRAZIL","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"DEP114","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"EMS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"EMS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"EMS \/ Undisclosed"},{"orgOrder":0,"company":"Mycenax Biotech","sponsor":"TSH Biopharm Corporation Limited","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"ENIA11","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Mycenax Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mycenax Biotech \/ TSH Biopharm Corporation Limited","highestDevelopmentStatusID":"10","companyTruncated":"Mycenax Biotech \/ TSH Biopharm Corporation Limited"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Etrozulimab","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"United Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JORDAN","productType":"Dietary Supplement","year":"2015","type":"Inapplicable","leadProduct":"Extensively Hydrolyzed Formula","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"United Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"United Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"United Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JORDAN","productType":"Dietary Supplement","year":"2016","type":"Inapplicable","leadProduct":"Extensively Hydrolyzed Formula","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"United Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"United Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"FEX60","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"University of Miami","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Fiber","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"University of Miami","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Miami \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"University of Miami \/ Pfizer Inc"},{"orgOrder":0,"company":"Japan Blood Products Organization","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"GB-0998","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Japan Blood Products Organization","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Japan Blood Products Organization \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Japan Blood Products Organization \/ Undisclosed"},{"orgOrder":0,"company":"Green Cross Lab Cell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"GC5107A","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Green Cross Lab Cell","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Green Cross Lab Cell \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Green Cross Lab Cell \/ Undisclosed"},{"orgOrder":0,"company":"Generium","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"RUSSIA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"GNR-069","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Generium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Generium \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Generium \/ Undisclosed"},{"orgOrder":0,"company":"Generium","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"RUSSIA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"GNR-069","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Generium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Generium \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Generium \/ Undisclosed"},{"orgOrder":0,"company":"Generium","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"RUSSIA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"GNR-086","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Generium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Generium \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Generium \/ Undisclosed"},{"orgOrder":0,"company":"ASIT biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Gpasit+Tm","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"ASIT biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ASIT biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ASIT biotech \/ Undisclosed"},{"orgOrder":0,"company":"BioTech Tools","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Gpasit+Tm","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"BioTech Tools","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioTech Tools \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BioTech Tools \/ Undisclosed"},{"orgOrder":0,"company":"BioTech Tools","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Gpasit+Tm","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"BioTech Tools","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioTech Tools \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BioTech Tools \/ Undisclosed"},{"orgOrder":0,"company":"BioTech Tools","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Gpasit+Tm","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"BioTech Tools","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioTech Tools \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BioTech Tools \/ Undisclosed"},{"orgOrder":0,"company":"BioTech Tools","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Gpasit+Tm","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"BioTech Tools","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioTech Tools \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BioTech Tools \/ Undisclosed"},{"orgOrder":0,"company":"Allergy Therapeutics","sponsor":"Inflamax Research | Metronomia Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Grass MATA MPL","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Allergy Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allergy Therapeutics \/ Inflamax Research | Metronomia Clinical Research","highestDevelopmentStatusID":"10","companyTruncated":"Allergy Therapeutics \/ Inflamax Research | Metronomia Clinical Research"},{"orgOrder":0,"company":"Allergy Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Grass MATA MPL","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Allergy Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allergy Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allergy Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ALK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Plant Extract\/Herbal","year":"2011","type":"Inapplicable","leadProduct":"Grass Pollen Allergen","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ALK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ALK \/ Undisclosed"},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"HCP1102","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Hanmi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hanmi Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hanmi Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"ALK","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"House Dust Mite Allergen Extract","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ALK \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"ALK \/ Syneos Health"},{"orgOrder":0,"company":"ALK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Dermatophagoides Pteronyssinus Extract","moa":"||Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ALK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ALK \/ Undisclosed"},{"orgOrder":0,"company":"Stallergenes Greer","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"House Dust Mites Allergen Extract","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Stallergenes Greer","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Stallergenes Greer \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Stallergenes Greer \/ Undisclosed"},{"orgOrder":0,"company":"Zhejiang Hisun Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"HS628","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Zhejiang Hisun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zhejiang Hisun Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zhejiang Hisun Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Grifols International","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Immune Globulin","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Grifols International \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Grifols International \/ Undisclosed"},{"orgOrder":0,"company":"Grifols International","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Immune Globulin","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Grifols International \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Grifols International \/ Undisclosed"},{"orgOrder":0,"company":"Grifols International","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Immune Globulin","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Grifols International \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Grifols International \/ Undisclosed"},{"orgOrder":0,"company":"Grifols International","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Immune Globulin","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Grifols International \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Grifols International \/ Undisclosed"},{"orgOrder":0,"company":"Biopharma Plasma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Immunoglobulin","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Biopharma Plasma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biopharma Plasma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biopharma Plasma \/ Undisclosed"},{"orgOrder":0,"company":"On Pharma","sponsor":"Hospital do Coracao","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Immunoglobulin","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"On Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"On Pharma \/ Hospital do Coracao","highestDevelopmentStatusID":"10","companyTruncated":"On Pharma \/ Hospital do Coracao"},{"orgOrder":0,"company":"Kedrion","sponsor":"Icon Plc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Immunoglobulin","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Kedrion","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kedrion \/ Icon Plc","highestDevelopmentStatusID":"10","companyTruncated":"Kedrion \/ Icon Plc"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Jitongning","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tianjin Tasly Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tianjin Tasly Group \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Chr. Hansen","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Probiotic","year":"2010","type":"Inapplicable","leadProduct":"Lactobacillus Paracasei","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Chr. Hansen","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Chr. Hansen"},{"orgOrder":0,"company":"Zurita Laboratorio Farmaceutico Ltda.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ECUADOR","productType":"Plant Extract\/Herbal","year":"2010","type":"Inapplicable","leadProduct":"Luffa Operculate","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Zurita Laboratorio Farmaceutico Ltda.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Zurita Laboratorio Farmaceutico Ltda. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zurita Laboratorio Farmaceutico Ltda. \/ Undisclosed"},{"orgOrder":0,"company":"EMS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BRAZIL","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Magn\u00f3lia","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"EMS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"EMS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"EMS \/ Undisclosed"},{"orgOrder":0,"company":"RDC Clinical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Maolactin","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"RDC Clinical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RDC Clinical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RDC Clinical \/ Undisclosed"},{"orgOrder":0,"company":"RDC Clinical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Maolactin","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"RDC Clinical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RDC Clinical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RDC Clinical \/ Undisclosed"},{"orgOrder":0,"company":"EMS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BRAZIL","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"MAZ-101","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"EMS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EMS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"EMS \/ Undisclosed"},{"orgOrder":0,"company":"medac","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"MC0518","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"medac","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"medac \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"medac \/ Undisclosed"},{"orgOrder":0,"company":"medac","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"MC0518","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"medac","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"medac \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"medac \/ Undisclosed"},{"orgOrder":0,"company":"MiMedx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Micronized Dhacm","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"MiMedx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MiMedx \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MiMedx \/ Undisclosed"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Linical | Datamap","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Mitizax","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abbott Laboratories \/ Linical | Datamap","highestDevelopmentStatusID":"10","companyTruncated":"Abbott Laboratories \/ Linical | Datamap"},{"orgOrder":0,"company":"Inmunotek","sponsor":"BioClever 2005","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"MM09","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Inmunotek","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inmunotek \/ BioClever 2005","highestDevelopmentStatusID":"10","companyTruncated":"Inmunotek \/ BioClever 2005"},{"orgOrder":0,"company":"Inmunotek","sponsor":"LAT Research | Xolomon Tree S.L.","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"MM09","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Inmunotek","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inmunotek \/ LAT Research | Xolomon Tree S.L.","highestDevelopmentStatusID":"10","companyTruncated":"Inmunotek \/ LAT Research | Xolomon Tree S.L."},{"orgOrder":0,"company":"Colgate Palmolive","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Nanohydroxyapatite","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Colgate Palmolive","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Paste","sponsorNew":"Colgate Palmolive \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Colgate Palmolive \/ Undisclosed"},{"orgOrder":0,"company":"ALK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Pangramin Slit Hdm Mix","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ALK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ALK \/ Undisclosed"},{"orgOrder":0,"company":"Prime Gene Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"PG-011","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Prime Gene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Prime Gene Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Prime Gene Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"University Hospital, Montpellier","sponsor":"H\u00f4pital Cochin | Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Vaccine","year":"2013","type":"Inapplicable","leadProduct":"Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"University Hospital, Montpellier","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital, Montpellier \/ H\u00f4pital Cochin | Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"University Hospital, Montpellier \/ H\u00f4pital Cochin | Pfizer Inc"},{"orgOrder":0,"company":"Allergy Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"PQGrass306","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Allergy Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergy Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allergy Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"QL0911","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Bio Farma","sponsor":"Hasan Sadikin General Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDONESIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Recombinant Hepatitis B Vaccine","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Bio Farma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio Farma \/ Hasan Sadikin General Hospital","highestDevelopmentStatusID":"10","companyTruncated":"Bio Farma \/ Hasan Sadikin General Hospital"},{"orgOrder":0,"company":"Beijing VDJBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Recombinant Humanized Anti-IL-6 Receptor Monoclonal Antibody","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Beijing VDJBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Beijing VDJBio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Beijing VDJBio \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"RO7790121","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"RO7790121","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"RO7790121","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"RO7790121","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"RO7790121","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Bio Farma","sponsor":"Center for Child Health Universitas Gadjah Mada | Cipto Mangunkusumo Hospital\/Department of Child Health, Faculty of Medicine, University of Indonesia | General Hospital of Shenyang Military Region","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDONESIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"SARS-CoV-2 Protein Subunit Recombinant Vaccine","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Bio Farma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio Farma \/ Center for Child Health Universitas Gadjah Mada | Cipto Mangunkusumo Hospital\/Department of Child Health, Faculty of Medicine, University of Indonesia | General Hospital of Shenyang Military Region","highestDevelopmentStatusID":"10","companyTruncated":"Bio Farma \/ Center for Child Health Universitas Gadjah Mada | Cipto Mangunkusumo Hospital\/Department of Child Health, Faculty of Medicine, University of Indonesia | General Hospital of Shenyang Military Region"},{"orgOrder":0,"company":"ALK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"SCH 39641","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ALK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ALK \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2015","type":"Inapplicable","leadProduct":"Short Ragweed Pollen Allergen Extract","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"GREER LABORATORIES","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2011","type":"Inapplicable","leadProduct":"Short Ragweed Pollen Allergen Extract","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"GREER LABORATORIES","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GREER LABORATORIES \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GREER LABORATORIES \/ Undisclosed"},{"orgOrder":0,"company":"ASST Fatebenefratelli Sacco","sponsor":"ALK","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ITALY","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Slitone","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"ASST Fatebenefratelli Sacco","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ASST Fatebenefratelli Sacco \/ ALK","highestDevelopmentStatusID":"10","companyTruncated":"ASST Fatebenefratelli Sacco \/ ALK"},{"orgOrder":0,"company":"SinoMab BioScience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"HONG KONG","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"SM03","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"SinoMab BioScience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SinoMab BioScience \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SinoMab BioScience \/ Undisclosed"},{"orgOrder":0,"company":"SinoMab BioScience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"HONG KONG","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"SM03","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"SinoMab BioScience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SinoMab BioScience \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SinoMab BioScience \/ Undisclosed"},{"orgOrder":0,"company":"SinoMab BioScience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"HONG KONG","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"SM03","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"SinoMab BioScience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SinoMab BioScience \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SinoMab BioScience \/ Undisclosed"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Sunpharma1505","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Undisclosed"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"TEV-45779","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"TILD","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Undisclosed"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"TILD","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Undisclosed"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"TILD","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"TQB3473","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"TQB3473","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Allergy Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Tree MATA MPL","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Allergy Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergy Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allergy Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Taisho Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"TS-152","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Taisho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taisho Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Taisho Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Neovii","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"US-ATG-F","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Neovii","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Neovii \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Neovii \/ Undisclosed"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"VRDN-003","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Viridian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"VRDN-003","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Viridian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"VRDN-003","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Viridian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"VRDN-003","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Viridian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"VRDN-003","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Viridian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Chulalongkorn University","sponsor":"Government Pharmaceutical Organization","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"THAILAND","productType":"Plant Extract\/Herbal","year":"2019","type":"Inapplicable","leadProduct":"Zingiber Cassumunar","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Chulalongkorn University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Chulalongkorn University \/ Government Pharmaceutical Organization","highestDevelopmentStatusID":"10","companyTruncated":"Chulalongkorn University \/ Government Pharmaceutical Organization"},{"orgOrder":0,"company":"Mabpharm Limitied","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"CMAB007","moa":"VEGF","graph1":"Immunology","graph2":"Phase III","graph3":"Mabpharm Limitied","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mabpharm Limitied \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mabpharm Limitied \/ Undisclosed"},{"orgOrder":0,"company":"Biocad","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"RUSSIA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"BCD-180","moa":"VEGF receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Biocad","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biocad \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biocad \/ Undisclosed"},{"orgOrder":0,"company":"Biocad","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"RUSSIA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"BCD-180","moa":"VEGF receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Biocad","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biocad \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biocad \/ Undisclosed"},{"orgOrder":0,"company":"University Medical Centre Ljubljana","sponsor":"Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SLOVENIA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Paricalcitol","moa":"Vitamin D receptor","graph1":"Immunology","graph2":"Phase III","graph3":"University Medical Centre Ljubljana","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Medical Centre Ljubljana \/ Abbott Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"University Medical Centre Ljubljana \/ Abbott Laboratories"},{"orgOrder":0,"company":"Cadrenal Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tecarfarin","moa":"Vitamin k epoxide reductase complex subunit 1 isoform 1","graph1":"Immunology","graph2":"Phase III","graph3":"Cadrenal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cadrenal Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cadrenal Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Catalyst Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Amifampridine Phosphate","moa":"Voltage-gated potassium channel","graph1":"Immunology","graph2":"Phase III","graph3":"Catalyst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Catalyst Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Catalyst Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Catalyst Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Amifampridine Phosphate","moa":"Voltage-gated potassium channel","graph1":"Immunology","graph2":"Phase III","graph3":"Catalyst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Catalyst Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Catalyst Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Tongren Hospital","sponsor":"Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Beijing Tongren Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Drops","sponsorNew":"Beijing Tongren Hospital \/ Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.","highestDevelopmentStatusID":"10","companyTruncated":"Beijing Tongren Hospital \/ Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd."},{"orgOrder":0,"company":"Ahn-Gook Pharmaceuticals","sponsor":"Seoul National University Bundang Hospital | Seoul National University Hospital | SMG-SNU Boramae Medical Center | Samsung Medical Center | Kyunghee University Medical Center | Konkuk University Medical Center | Inha University | Seoul St. Mary's Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Ahn-Gook Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ahn-Gook Pharmaceuticals \/ Seoul National University Bundang Hospital | Seoul National University Hospital | SMG-SNU Boramae Medical Center | Samsung Medical Center | Kyunghee University Medical Center | Konkuk University Medical Center | Inha University | Seoul St. Mary's Hospital","highestDevelopmentStatusID":"10","companyTruncated":"Ahn-Gook Pharmaceuticals \/ Seoul National University Bundang Hospital | Seoul National University Hospital | SMG-SNU Boramae Medical Center | Samsung Medical Center | Kyunghee University Medical Center | Konkuk University Medical Center | Inha University | Seoul St. Mary's Hospital"},{"orgOrder":0,"company":"Circassia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Circassia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Circassia \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Circassia \/ Undisclosed"},{"orgOrder":0,"company":"ALK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ALK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ALK \/ Undisclosed"},{"orgOrder":0,"company":"SetPoint Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"SetPoint Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SetPoint Medical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SetPoint Medical \/ Undisclosed"},{"orgOrder":0,"company":"Genrix Biopharmaceutical Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"GR1802","moa":"IL-4R?","graph1":"Immunology","graph2":"Phase III","graph3":"Genrix Biopharmaceutical Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genrix Biopharmaceutical Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Genrix Biopharmaceutical Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"VRDN-003","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Viridian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Afimkibart","moa":"VEGI","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"BDB001","moa":"Toll-like receptor (TLR)","graph1":"Immunology","graph2":"Phase III","graph3":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Staidson (Beijing) Biopharmaceuticals Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Staidson (Beijing) Biopharmaceuticals Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"JIANGSU VCARE PHARMATECH CO., LTD","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"VC005","moa":"JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"JIANGSU VCARE PHARMATECH CO., LTD","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"JIANGSU VCARE PHARMATECH CO., LTD \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"JIANGSU VCARE PHARMATECH CO., LTD \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Duvakitug","moa":"TNFSF15","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Sanofi","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Duvakitug","moa":"TNFSF15","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Sanofi","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Duvakitug","moa":"TNFSF15","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Sanofi","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Duvakitug","moa":"TNFSF15","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Rilzabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Icotrokinra","moa":"IL23R","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Genrix Biopharmaceutical Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"GR1802","moa":"IL-4R?","graph1":"Immunology","graph2":"Phase III","graph3":"Genrix Biopharmaceutical Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genrix Biopharmaceutical Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Genrix Biopharmaceutical Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Intas Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Licensing Agreement","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio-Thera Solutions \/ Intas Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera Solutions \/ Intas Pharmaceuticals"},{"orgOrder":0,"company":"TJ Biopharma Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Plonmarlimab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Immunology","graph2":"Phase III","graph3":"TJ Biopharma Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"TJ Biopharma Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"TJ Biopharma Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Chengdu Kangnuoxing Biopharma,Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Stapokibart","moa":"IL-4R\u03b1","graph1":"Immunology","graph2":"Phase III","graph3":"Chengdu Kangnuoxing Biopharma,Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chengdu Kangnuoxing Biopharma,Inc. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Chengdu Kangnuoxing Biopharma,Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"VRDN-003","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zai Lab \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zai Lab \/ Undisclosed"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Fernanda P Silveira","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Rezafungin","moa":"Candida","graph1":"Immunology","graph2":"Phase III","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Melinta Therapeutics \/ Fernanda P Silveira","highestDevelopmentStatusID":"10","companyTruncated":"Melinta Therapeutics \/ Fernanda P Silveira"},{"orgOrder":0,"company":"Janssen-Cilag","sponsor":"Frank Behrens","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ITALY","productType":"Cytotoxic Drug","year":"2017","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Immunology","graph2":"Phase III","graph3":"Janssen-Cilag","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Janssen-Cilag \/ Frank Behrens","highestDevelopmentStatusID":"10","companyTruncated":"Janssen-Cilag \/ Frank Behrens"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Julia Brown","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2010","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Julia Brown","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Julia Brown"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Heleen Grootjans","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ITALY","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase III","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Chiesi Group \/ Heleen Grootjans","highestDevelopmentStatusID":"10","companyTruncated":"Chiesi Group \/ Heleen Grootjans"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Ramesh Prasad","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Mycophenolate Mofetil","moa":"Inosine-5'-monophosphate dehydrogenase (IMPDH)","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Ramesh Prasad","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Ramesh Prasad"},{"orgOrder":0,"company":"Biogen","sponsor":"Farsad Eskandary","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Felzartamab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Immunology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biogen \/ Farsad Eskandary","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Farsad Eskandary"},{"orgOrder":0,"company":"BASF","sponsor":"Joe Chan","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NORWAY","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Omega-3-Acid Ethyl Esters 90","moa":"steroids (androgens","graph1":"Immunology","graph2":"Phase III","graph3":"BASF","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BASF \/ Joe Chan","highestDevelopmentStatusID":"10","companyTruncated":"BASF \/ Joe Chan"},{"orgOrder":0,"company":"Green Cross Lab Cell","sponsor":"Ho Cheol Shin","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Human Placenta Hydrolysate","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Green Cross Lab Cell","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Green Cross Lab Cell \/ Ho Cheol Shin","highestDevelopmentStatusID":"10","companyTruncated":"Green Cross Lab Cell \/ Ho Cheol Shin"}]

    Find Immunology Drugs in Phase III Clinical Development in UNITED STATES

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Rilzabrutinib

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related...

                            Details : Rilzabrutinib is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Immunoglobulin G4-Related Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 24, 2025

                            Lead Product(s) : Rilzabrutinib

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Duvakitug

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Teva Pharmaceutical Industries

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Seve...

                            Details : Duvakitug is a Antibody, Unconjugated drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Crohn Disease.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            September 22, 2025

                            Lead Product(s) : Duvakitug

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Teva Pharmaceutical Industries

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Duvakitug

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Teva Pharmaceutical Industries

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Sev...

                            Details : Duvakitug is a Antibody, Unconjugated drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Crohn Disease.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            September 22, 2025

                            Lead Product(s) : Duvakitug

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Teva Pharmaceutical Industries

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Duvakitug

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Teva Pharmaceutical Industries

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Seve...

                            Details : Duvakitug is a Antibody, Unconjugated drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Colitis, Ulcerative.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            September 22, 2025

                            Lead Product(s) : Duvakitug

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Teva Pharmaceutical Industries

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Duvakitug

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Teva Pharmaceutical Industries

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Sev...

                            Details : Duvakitug is a Antibody, Unconjugated drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Colitis, Ulcerative.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            September 22, 2025

                            Lead Product(s) : Duvakitug

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Teva Pharmaceutical Industries

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            AbbVie Inc

                            U.S.A
                            Aquaexpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Risankizumab

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Risankizumab in Young Participants with Ulcerative Colitis

                            Details : Risankizumab is a Antibody drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Colitis, Ulcerative.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            July 17, 2025

                            Lead Product(s) : Risankizumab

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Rilzabrutinib

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Oral Rilzabrutinib Safety and Efficacy In ITP Adults After First-Line Failure

                            Details : Rilzabrutinib is a Other Small Molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Purpura, Thrombocytopenic, Idiopathic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 06, 2025

                            Lead Product(s) : Rilzabrutinib

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            AbbVie Inc

                            U.S.A
                            Aquaexpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Risankizumab

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Coli...

                            Details : Risankizumab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Colitis, Ulcerative.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            March 18, 2025

                            Lead Product(s) : Risankizumab

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            AbbVie Inc

                            U.S.A
                            Aquaexpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Upadacitinib,Corticosteroid

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            AbbVie gets Positive CHMP Opinion for RINVOQ® in Giant Cell Arteritis Treatment

                            Details : Rinvoq (upadacitinib) is a FDA approved selective JAK inhibitor that is being investigated in adult patients with giant cell arteritis in a Phase 3 clinical trial.

                            Product Name : Rinvoq

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 28, 2025

                            Lead Product(s) : Upadacitinib,Corticosteroid

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Dupilumab

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Regeneron Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA Accepts Dupixent sBLA for Chronic Spontaneous Urticaria Treatment

                            Details : Dupixent (dupilumab) is an approved monoclonal antibody works by inhibiting IL-4 and IL-13. It is being investigated for the treatment in 12 years and older with chronic spontaneous urticaria.

                            Product Name : Dupixent

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            November 15, 2024

                            Lead Product(s) : Dupilumab

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Regeneron Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth